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Abstract
Personalized medicine has received increasing attention among statisticians, com-
puter scientists, and clinical practitioners. A major component of personalized medicine
is the estimation of individualized treatment rules (ITRs). Recently, Zhao et al. (2012)
proposed outcome weighted learning (OWL) to construct ITRs that directly optimize
the clinical outcome. Although OWL opens the door to introducing machine learning
techniques to optimal treatment regimes, it still has some problems in performance.
(1) The estimated ITR of OWL is affected by a simple shift of the outcome. (2) The
rule from OWL tries to keep treatment assignments that subjects actually received.
(3) There is no variable selection mechanism with OWL. All of them weaken the finite
sample performance of OWL. In this article, we propose a general framework, called
Residual Weighted Learning (RWL), to alleviate these problems, and hence to improve
finite sample performance. Unlike OWL which weights misclassification errors by clin-
ical outcomes, RWL weights these errors by residuals of the outcome from a regression
fit on clinical covariates excluding treatment assignment. We utilize the smoothed ramp
loss function in RWL, and provide a difference of convex (d.c.) algorithm to solve the
corresponding non-convex optimization problem. By estimating residuals with linear
models or generalized linear models, RWL can effectively deal with different types of
outcomes, such as continuous, binary and count outcomes. We also propose variable
selection methods for linear and nonlinear rules, respectively, to further improve the
performance. We show that the resulting estimator of the treatment rule is consistent.
We further obtain a rate of convergence for the difference between the expected outcome
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using the estimated ITR and that of the optimal treatment rule. The performance of
the proposed RWL methods is illustrated in simulation studies and in an analysis of
cystic fibrosis clinical trial data.
Keywords: Optimal Treatment Regime, RKHS, Universal consistency, Convergence Rate,
Residuals, Martingale residuals.
1 Introduction
Personalized medicine is a medical paradigm that utilizes individual patient information to
optimize patients health care. Recently, personalized medicine has received much attention
among statisticians, computer scientists, and clinical practitioners. The primary motivation
is the well-established fact that patients often show significant heterogeneity in response
to treatments. For instance, in a recent study, it was demonstrated that the optimal
timing for the initiation of antiretroviral therapy (ART) varies in patients co-infected with
human immunodeficiency virus and tuberculosis. Patients with CD4+ T-cell counts of less
than 50 per cubic millimeter benefited substantially from earlier ART with a lower rate of
new AIDS-defining illnesses and mortality as compared with later ART, while those with
larger CD4+ T-cell counts did not have such a benefit (Havlir et al. 2011). The inherent
heterogeneity across patients suggests a transition from the traditional “one size fits all”
approach to modern personalized medicine.
A major component of personalized medicine is the estimation of individualized treat-
ment rules (ITRs). Formally, the goal is to seek a rule that assigns a treatment, from
among a set of possible treatments, to a patient based on his or her clinical, prognostic or
genomic characteristics. The individualized treatment rules are also called optimal treat-
ment regimes. There is a significant literature on individualized treatment strategies based
on data from clinical trials or observational studies (Murphy 2003; Robins 2004; Zhang
et al. 2012; Zhao et al. 2009). Much of the work relies on modeling either the conditional
mean outcomes or contrasts between mean outcomes. These methods obtain ITRs indi-
rectly by inverting the regression estimates instead of directly optimizing the decision rule.
For instance, Qian and Murphy (2011) applied a two-step procedure that first estimates a
conditional mean for the outcome and then determines the treatment rule by comparing
the conditional means across various treatments. The success of these indirect approaches
highly depends on correct specification of posited models and on the precision of model
estimates.
In contrast, Zhao et al. (2012) proposed outcome weighted learning (OWL), using data
from a randomized clinical trial, to construct an ITR that directly optimizes the clinical out-
come. They cast the treatment selection problem as a weighted classification problem, and
apply state-of-the-art support vector machines for implementation. This approach opens
the door to introducing machine learning techniques into this area. However, there is still
significant room for improved performance. First, the estimated ITR of OWL is affected
by a simple shift of the outcome. This behavior makes the estimate of OWL unstable. Sec-
ond, since OWL requires the outcome to be nonnegative, OWL works similarly to weighted
classification, in which misclassification errors, the differences between the estimated and
true treatment assignments, are targeted to be reduced. Hence the ITR estimated by OWL
tries to keep treatment assignments that subjects actually received. This is not always ideal
since treatments are randomly assigned in the trial, and the probability is slim that the
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majority of subjects are assigned optimal treatments. Third, OWL does not have variable
selection features. When there are many clinical covariates which are not related to the
heterogeneous treatment effects, variable selection is critical to the performance.
To alleviate these problems, we propose a new method, called Residual Weighted Learn-
ing (RWL). Unlike OWL which weights misclassification errors by clinical outcomes, RWL
weights these errors by residuals from a regression fit of the outcome. The predictors of
the regression model include clinical covariates, but exclude treatment assignment. Thus
the residuals better reflect the heterogeneity of treatment effects. Since some residuals are
negative, the hinge loss function used in OWL is not appropriate. We instead utilize the
smoothed ramp loss function, and provide a difference of convex (d.c.) algorithm to solve
the corresponding non-convex optimization problem. The smoothed ramp loss resembles
the ramp loss (Collobert et al. 2006), but it is smooth everywhere. It is well known that
ramp loss related methods are shown to be robust to outliers (Wu and Liu 2007). The
robustness to outliers for the smoothed ramp loss is helpful for RWL, especially when resid-
uals are poorly estimated. Moreover, through using residuals, RWL is able to deal relatively
easily with almost all types of outcomes. For example, RWL can work with generalized lin-
ear models to construct ITRs for count/rate outcomes. We also propose variable selection
approaches in RWL for linear and nonlinear rules, respectively, to further improve finite
sample performance.
The theoretical analysis of RWL focuses on two aspects, universal consistency and
convergence rate. The notion of universal consistency is borrowed from machine learning.
It requires for a learning method that when the sample size approaches infinity the method
eventually learns the Bayes rule without knowing any specifics of the distribution of the
data. We show that RWL with a universal kernel (e.g. Gaussian RBF kernel) is universally
consistent. In machine learning, there is a famous “no-free-lunch theorem”, which states
that the convergence rate of any particular learning rule may be arbitrarily slow (Devroye
et al. 1996). In this article, we prove the “no-free-lunch theorem” for finding ITRs. Thus
the rate of convergence studies for a particular rule must necessarily be accompanied by
conditions on the distribution of the data. For RWL with Gaussian RBF kernel, we show
that under the geometric noise condition (Steinwart and Scovel 2007) the convergence rate
is as high as n−1/3.
At first glance, one may think that there is not a large difference between OWL and
RWL except that RWL uses residuals as alternative outcomes. Actually, RWL enjoys many
benefits from this simple modification. First, by using residuals of outcomes, RWL is able
to reduce the variability introduced by the original outcomes. Second, since the numbers of
subjects with positive and negative residuals are generally balanced, the ITR determined
by RWL favors neither the treatment assignments that subjects actually received nor their
opposites. Because of the above reasons, RWL improves finite sample performance. Third,
RWL possesses location-scale invariance with respect to the original outcomes. Specifically,
the estimated rule of RWL is invariant to a shift of the outcome; it is invariant to a scaling
of the outcome with a positive number; the rule from RWL that maximizes the outcome is
opposite to the rule that minimizes the outcome. These are intuitively sensible.
The contributions of this article are summarized as follows. (1) We propose the general
framework of Residual Weighted Learning to estimate individualized treatment rules. By
estimating residuals with linear or generalized linear models, RWL can effectively deal with
different types of outcomes, such as continuous, binary and count outcomes. For censored
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survival outcomes, RWL could potentially utilize martingale residuals, although theoretical
justification is still under development. (2) We develop variable selection techniques in
RWL to further improve performance. (3) We present a comprehensive theoretical analysis
of RWL on universal consistency and convergence rate. (4) As a by-product, we show
the “no-free-lunch theorem” for ITRs that the convergence rate of any particular rule may
be arbitrarily slow. This is a generic result, and it applies to any algorithm for optimal
treatment regimes.
The remainder of the article is organized as follows. In Section 2, we discuss Outcome
Weighted Learning (OWL) and propose Residual Weighted Learning (RWL) to improve
finite sample performance for continuous outcomes. Then we develop a general framework
for RWL to handle other types of outcomes, and use binary and count/rate outcomes
as examples. In Section 3, we establish consistency and convergence rate results for the
estimated rules. The variable selection techniques for RWL are discussed in Section 4.
We present simulation studies to evaluate performance of the proposed methods in Section
5. The method is then illustrated on the EPIC cystic fibrosis randomized clinical trial
(Treggiari et al. 2009, 2011) in Section 6. We conclude the article with a discussion in
Section 7. All proofs are given in Appendix.
2 Methodology
2.1 Outcome Weighted Learning
Consider a two-arm randomized trial. We observe a triplet (X, A,R) from each patient,
where X = (X1, · · · ,Xp)T ∈ X denotes the patient’s clinical covariates, A ∈ A = {1,−1}
denotes the treatment assignment, and R is the observed clinical outcome, also called the
“reward” in the literature on reinforcement learning. We assume that R is bounded, and
larger values of R are more desirable. An individualized treatment rule (ITR) is a function
from X to A. Let π(a,x) := P (A = a|X = x) be the probability of being assigned
treatment a for patients with clinical covariates x. It is predefined in the trial design.
Here we consider a general situation. In most clinical trials, the treatment assignment is
independent of X, but in some designs, such as stratified designs, A may depend on X.
We assume π(a,x) > 0 for all a ∈ A and x ∈ X .
An optimal ITR is a rule that maximizes the expected outcome under this rule. Math-
ematically, the expected outcome under any ITR d is given as
E(R|A = d(X)) = E
(
R
π(A,X)
I
(
A = d(X)
))
, (1)
where I(·) is the indicator function. Interested readers may refer to Qian and Murphy
(2011) and Zhao et al. (2012) regarding the derivation of (1). This expectation is called the
value function associated with the rule d, and is denoted V (d). In other words, the value
function V (d) is the expected value of R given that the rule d(X) is applied to the given
population of patients. An optimal ITR d∗ is a rule that maximizes V (d). Finding d∗ is
equivalent to the following minimization problem:
d∗ ∈ argmin
d
E
(
R
π(A,X)
I
(
A 6= d(X)
))
. (2)
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Zhao et al. (2012) viewed this as a weighted classification problem, in which one wants to
classify A using X but also weights each misclassification error by R/π(A,X).
Assume that the observed data {(xi, ai, ri) : i = 1, · · · , n} are collected independently.
For any decision function f(x), let df (x) = sign
(
f(x)
)
be the associated rule, where
sign(u) = 1 for u > 0 and −1 otherwise. The particular choice of the value of sign(0) is
not important. In this article, we fix sign(0) = −1. Using the observed data, the weighted
classification error in (2) can be approximated by the empirical risk
1
n
n∑
i=1
ri
π(ai,xi)
I
(
df (xi) 6= ai
)
. (3)
The optimal decision function fˆ(x) is the one that minimizes the outcome weighted error
(3).
It is well known that empirical risk minimization for a classification problem with the 0-1
loss function is an NP-hard problem. To alleviate this difficulty, one often finds a surrogate
loss to replace the 0-1 loss. Outcome weighted learning (OWL) proposed by Zhao et al.
(2012) uses the hinge loss function, and also applies the regularization technique used in
the support vector machine (SVM) (Vapnik 1998). In other words, instead of minimizing
(3), OWL aims to minimize
1
n
n∑
i=1
ri
π(ai,xi)
(
1− aif(xi)
)
+
+ λ||f ||2, (4)
where (u)+ = max(u, 0) is the positive part of u, ||f || is some norm for f , and λ is a tuning
parameter controlling the trade-off between empirical risk and complexity of the decision
function f .
OWL opens the door to the application of statistical learning techniques to personalized
medicine. However, this approach is not perfect. First, a simple shift on the outcome R
should not affect the optimal decision rule, as seen from (1) and (2). That is, d∗ in (2) does
not change if R is replaced by R+ c, for any constant c. Unfortunately this nice invariance
property does not hold for the decision function fˆ(x) of OWL in (4) when ri is replaced
by ri + c. Consider an extreme case where c is very large and π(1,x) = π(−1,x) = 0.5
for all x ∈ X , the weights (ri+ c)/π(ai,xi) are almost identical, and the weighted problem
is approximately transformed to an unweighted one. Hence the performance of OWL can
be affected by a simple shift of R. Second, OWL further assumes that R is nonnegative
to gain computational efficiency from convex programming. A direct consequence of this
assumption, as seen from (3), is that the treatment regime df (xi) tends to match the
treatment ai that was actually assigned to the patient, especially when the decision function
f is chosen from a rich class of functions. This property is not ideal for data from a
randomized clinical trial, since treatments are actually randomly assigned to patients.
2.2 Residual Weighted Learning
In this section, we only consider the case that the outcome R is continuous, and extend the
framework to other types of outcomes in Section 2.4.
As demonstrated previously, the decision rule in (2) is invariant to a shift of outcome
R by any constant. Moreover, Lemma 2.1 shows that d∗ in (2) is invariant under a shift
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of R by a function of X. That is, d∗ remains unchanged if R is replaced by R − g(X)
for any function g, as long as g is not related to d. So there is an optimal solution fˆ
in (4) corresponding to a particular function g, when ri is replaced by ri − g(xi), and the
associated rule dˆf = sign(fˆ) can be seen as an estimated optimal rule in (2). As g varies, we
obtain a collection of dˆf ’s. When the sample size is very large, these dˆf ’s perform similarly
by the infinite sample property of OWL shown in Zhao et al. (2012). However, when the
sample size is limited, as in clinical settings, the choice of g is critical to the performance
of OWL. Zhao et al. (2012) did not delve deeply into this problem. In this article, we will
provide a solution to this, and improve finite sample performance.
Lemma 2.1. For any measurable g : X → R and any probability distribution for (X, A,R),
E
(
R− g(X)
π(A,X)
I
(
A 6= d(X))) = E( R
π(A,X)
I
(
A 6= d(X)))− E (g(X)) .
Intuitively, the function g with the smallest variance of
R− g(X)
π(A,X)
I
(
A 6= d(X)) is a
good choice. However, such a function depends on the decision rule d, as shown in the
following theorem. The proof of the theorem is provided in Appendix.
Theorem 2.2. Among all measurable g : X → R, g˜(X) = E
(
R
π(A,X)
I
(
A 6= d(X))∣∣∣X)
is the function g that minimizes the variance of
R− g(X)
π(A,X)
I
(
A 6= d(X)).
Our purpose is to find a function g, which is not related to d, to reduce the variance of
R− g(X)
π(A,X)
I
(
A 6= d(X)) as much as possible. As shown in the proof, the minimizer g˜ can
be written as,
g˜(X) = E(R|X, A = 1)I(d(X) 6= 1)+ E(R|X, A = −1)I(d(X) 6= −1).
That is, g˜(X) jumps between E(R|X, A = 1) and E(R|X, A = −1) as d(X) varies. Hence
when d is unknown, a reasonable choice of g is
g∗(X) =
E(R|X, A = 1) + E(R|X, A = −1)
2
= E
(
R
2π(A,X)
|X
)
. (5)
We propose to minimize the following empirical risk, rather than the original one in (3):
1
n
n∑
i=1
ri − gˆ∗(xi)
π(ai,xi)
I
(
df (xi) 6= ai
)
, (6)
where gˆ∗ is an estimate of g∗. For simplicity, let rˆi = ri− gˆ∗(xi) be the estimated residual.
Here, we do not weight misclassification errors by clinical outcomes as OWL does, and
instead we weight them by residuals from a regression fit of outcomes. Thus the optimal
decision function is invariant under any translation of clinical outcomes. We call the method
Residual Weighted Learning (RWL).
RWL also has the following interpretation. The outcome R can be characterized as
R = µ(X) + δ(X) ·A+ ǫ,
6
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Figure 1: Example of residual weighted learning. The raw data are shown on the left,
consisting of a single covariate X, treatment assignment A = 1 or −1, and continuous
outcome R with E(R|X,A) = 3X + XA. The allocation ratio is 1:1. The residuals,
R− 3X, are shown on the right.
where ǫ is the mean zero random error. µ(X) reflects common effects of clinical covariates
X for both treatment arms. It is easy to see that µ(X) = (E(R|X, A = 1) + E(R|X, A =
−1))/2, so the residual, R− g∗(X), in RWL is just δ(X) ·A+ ǫ, which captures all sources
of heterogeneous treatment effects. The rationale of optimal treatment regimes is to keep
treatment assignments that subjects have actually received if those subjects are observed
to have large outcomes, and to switch assignments if outcomes are small. However, the
largeness and smallness for outcomes are relative. A rather large outcome may still be con-
sidered as small when compared with subjects having similar clinical covariates, as shown
in Figure 1. Outcomes are not comparable among subjects with different clinical covariates,
while the residual, by removing common covariates effects, is a better measurement. Fig-
ure 1 illustrates how residuals work using an example with a single covariate X. The raw
data are shown on the left, and residuals are shown on the right. Residuals are comparable
among subjects, and larger residuals represent better outcomes.
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Another benefit from using residuals is a clear cut-off, i.e. 0, to distinguish between
subjects with good and poor clinical outcomes. To minimize the empirical risk in (6), for
subjects with positive residuals, RWL is apt to recommend the same treatment assignments
that subjects have actually received; for subjects with negative residuals, RWL is more likely
to give the opposite treatment assignments to what they have received. The optimal ITR is
the one maximizing the conditional expected outcome given in (1). An empirical estimator
of (1) is,
1
n
n∑
i=1
ri
π(ai,xi)
I
(
d(xi) = ai
)
. (7)
Though it is unbiased, it may give an estimate outside the range of R. While for finite
samples a better estimator of (1) as shown in Murphy (2005) is,
1
n
∑n
i=1
riI
(
d(xi)=ai
)
π(ai,xi)
1
n
∑n
i=1
I
(
d(xi)=ai
)
π(ai,xi)
. (8)
The denominator is an estimator of E
(
I
(
A=d(X)
)
π(A,X)
)
. Similar reasoning as that used in
the proof of Lemma 2.1 yields E
(
I
(
A=d(X)
)
π(A,X)
)
= 1. The estimator 1n
∑n
i=1
I
(
d(xi)=ai
)
π(ai,xi)
is
called the treatment matching factor in this article. The factor varies between 0 and 2.
If a rule favors treatment assignments that subjects have actually received, its treatment
matching factor is greater than 1, while in contrast if a rule prefers the opposite treatment
assignments, its treatment matching factor is less than 1. For a randomized clinical trial,
we expect that the estimated rule is associated with a treatment matching factor close to 1.
For OWL, since all the weights are nonnegative, the estimated rule of OWL tends to keep,
if possible, the treatments that subjects actually received. Thus the associated treatment
matching factor would be greater than 1, especially when the sample size is small, or when
a complicated rule is applied. Hence the estimator in (8) might not be large even though
(7) is maximized. RWL alleviates this problem by using residuals to make an initial guess
on the optimal rule. Owing to the balance between subjects with positive and negative
residuals, RWL implicitly finds a rule with its treatment matching factor close to 1.
There are many ways to estimate g∗. In this article, we consider two models. The
first one is the main effects model. Assume that E
(
R
2π(A,X)
|X
)
= β0 +X
Tβ, where
β = (β1, · · · , βp)T . The estimates βˆ and βˆ0 can be obtained by minimizing the sum of
weighted squares,
n∑
i=1
1
2π(ai,xi)
(ri − β0 − xTi β)2.
It can be solved easily by almost any statistical software. Then the estimate is gˆ∗(x) =
βˆ0 + x
T βˆ. The second is the null model. Assume that E
(
R
2π(A,X)
|X
)
= β0. It is easy
to obtain gˆ∗(x) = βˆ0 =
∑n
i=1
ri
π(ai,xi)
/
∑n
i=1
1
π(ai,xi)
.
In summary, we propose a method called Residual Weighted Learning to identify the
optimal ITR by minimizing the residual weighted classification error (6). The impact of
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using residuals is two-fold: it stabilizes the variance of the value function and controls the
treatment matching factor. Both improve finite sample performance.
2.3 Implementation of RWL
As in OWL, we intend to use a surrogate loss function to replace the 0-1 loss in (6). Since
some residuals are negative, convex surrogate functions do not work here. We consider a
non-convex loss
T (u) =


0 if u ≥ 1,
(1− u)2 if 0 ≤ u < 1,
2− (1 + u)2 if − 1 ≤ u < 0,
2 if u < −1.
It is called the smoothed ramp loss in this article. Figure 2 shows the hinge loss, ramp
loss and smoothed ramp loss functions. The hinge loss is the loss function used in support
vector machines (Vapnik 1998). The ramp loss (Collobert et al. 2006) is also called the
truncated hinge loss function (Wu and Liu 2007). It is well known that by truncating the
unbounded hinge loss, ramp loss related methods are shown to be robust to outliers in
the training data for the classification problem (Wu and Liu 2007). Compared with the
ramp loss, the smoothed ramp loss is smooth everywhere. Hence it has computational
advantages in optimization. Moreover, the smoothed ramp loss, which resembles the ramp
loss, is robust to outliers too. In the framework of RWL, subjects who did not receive
optimal treatment assignments but had large positive residuals, or those who did receive
optimal assignments but had large negative residuals may be considered as outliers. The
robustness to outliers for the smoothed ramp loss is helpful in dealing with outliers in the
setting of optimal treatment regimes, especially when residuals are poorly estimated, or
when the outcome R has a large variance.
We incorporate RWL into the regularization framework, and aim to minimize
1
n
n∑
i=1
rˆi
π(ai,xi)
T (aif(xi)) +
λ
2
||f ||2, (9)
where ||f || is some norm for f , and λ is a tuning parameter. Recall that rˆi is the estimated
residual. The smoothed ramp loss function T (u) is symmetric about the point (0, 1) as
shown in Figure 2(c). A nice property that comes from the symmetry is that the rule that
minimizes the outcome R (i.e. maximizes −R) is just opposite to the rule that maximizes
R. This is intuitively sensible. However, OWL does not possess this property.
We derive an algorithm for linear RWL in Section 2.3.1, and then generalize it to the
case of nonlinear learning through kernel mapping in Section 2.3.2.
2.3.1 Linear Decision Rule for Optimal ITR
Suppose that the decision function f(x) that minimizes (9) is a linear function of x, i.e.
f(x) = wTx+ b. Then the associated ITR will assign a subject with clinical covariates x
into treatment 1 if wTx+ b > 0 and −1 otherwise. In (9), we define ||f || as the Euclidean
9
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(d) Decomposition
Figure 2: Hinge loss (a), ramp loss (b), and smoothed ramp loss (c) functions. (d) shows
the difference of convex decomposition of the smoothed ramp loss, T (u) = φ1(u)− φ0(u).
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norm of w. Then minimizing (9) can be rewritten as
min
w,b
λ
2
wTw +
1
n
n∑
i=1
rˆi
π(ai,xi)
T
(
ai(w
Txi + b)
)
. (10)
The smoothed ramp loss is a non-convex loss, and as a result, the optimization problem
in (10) involves non-convex minimization. This optimization problem is difficult since
there are many local minima or stationary points. For instance, any (w, b) with w = 0
and |b| ≥ 1 is a stationary point. Similar with the robust truncated hinge loss support
vector machine (Wu and Liu 2007), we apply the d.c. (Difference of Convex) algorithm
(An and Tao 1997) to solve this non-convex minimization problem. The d.c. algorithm is
also known as the Concave-Convex Procedure (CCCP) in the machine learning community
(Yuille and Rangarajan 2003). Assume that an objective function can be rewritten as the
sum of a convex part Qvex(Θ) and a concave part Qcav(Θ). The d.c. algorithm as shown
in Algorithm 1 solves the non-convex optimization problem by minimizing a sequence of
convex subproblems. One can easily see that the d.c. algorithm is a special case of the
Majorize-Minimization (MM) algorithm.
Algorithm 1: The d.c. algorithm for minimizing Q(Θ) = Qvex(Θ) +Qcav(Θ).
Initialize Θ(0)
repeat
Θ(t+1) = argminΘQvex(Θ)+ < Q
′
cav(Θ
(t)),Θ >
until convergence of Θ(t)
Let
φs(u) =


0 if u ≥ s
(s− u)2 if s− 1 ≤ u < s
2s− 2u− 1 if u < s− 1
.
Note that φs is smooth. We have a difference-of-convex decomposition of the smoothed
ramp loss,
T (u) = φ1(u)− φ0(u), (11)
as shown in Figure 2(d). Denote Θ as (w, b). Applying (11), the objective function in (10)
can be decomposed as
Qs(Θ) =
λ
2
wTw +
1
n
n∑
i=1
[
φ1(ui)I(rˆi > 0) + φ0(ui)I(rˆi < 0)
] |rˆi|
π(ai,xi)︸ ︷︷ ︸
Qvex(Θ)
− 1
n
n∑
i=1
[
φ1(ui)I(rˆi < 0) + φ0(ui)I(rˆi > 0)
] |rˆi|
π(ai,xi)︸ ︷︷ ︸
Qcav(Θ)
,
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where ui = ai(w
Txi + b). For simplicity, we introduce the notation,
βi =
∂Qcav
∂ui
= − 1
n
[dφ1(ui)
dui
I(rˆi < 0) +
dφ0(ui)
dui
I(rˆi > 0)
] |rˆi|
π(ai,xi)
, (12)
for i = 1, · · · , n. Thus the convex subproblem at the (t+1)’th iteration of the d.c. algorithm
is
min
w,b
λ
2
wTw +
1
n
n∑
i=1
[
φ1(ui)I(rˆi > 0) + φ0(ui)I(rˆi < 0)
] |rˆi|
π(ai,xi)
+
n∑
i=1
β
(t)
i ui. (13)
There are many efficient methods available for solving smooth unconstrained optimization
problems. In this article, we use the limited-memory Broyden-Fletcher-Goldfarb-Shanno
(L-BFGS) algorithm (Nocedal 1980). L-BFGS is a quasi-Newton method that approxi-
mates the Broyden-Fletcher-Goldfarb-Shanno (BFGS) algorithm using a limited amount of
computer memory. For more information on the quasi-Newton method and L-BFGS, see
Nocedal and Wright (2006).
The procedure is summarized in the following algorithm:
Algorithm 2: The d.c. algorithm for linear RWL with the smoothed ramp loss
Set ǫ to a small quantity, say, 10−8
Initialize β
(0)
i =
2|rˆi|
nπ(ai,xi)
I(rˆi < 0)
repeat
• Compute (wˆ, bˆ) by solving (13),
• Update ui = ai(wˆTxi + bˆ)
• Update β(t+1)i by (12)
until ||β(t+1) − β(t)||∞ < ǫ
2.3.2 Nonlinear Decision rule for Optimal ITR
For a nonlinear decision rule, the decision function f(x) is represented by h(x) + b with
h(x) ∈ HK and b ∈ R, where HK is a reproducing kernel Hilbert space (RKHS) associated
with a Mercer kernel function K. The kernel function K(·, ·) is a positive definite function
mapping from X ×X to R. The norm in HK , denoted by || · ||K , is induced by the following
inner product:
< f, g >K=
n∑
i=1
m∑
j=1
αiβjK(xi,xj),
for f(·) =∑ni=1 αiK(·,xi) and g(·) =∑mj=1 βjK(·,xj). Then minimizing (9) can be rewrit-
ten as
min
h,b
λ
2
||h||2K +
1
n
n∑
i=1
rˆi
π(ai,xi)
T
(
ai
(
h(xi) + b
))
. (14)
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Due to the representer theorem (Kimeldorf and Wahba 1971), the nonlinear problem can
be reduced to finding finite-dimensional coefficients vi, and h(x) can be represented as∑n
j=1 vjK(x,xj). Thus the problem (14) is transformed to
min
v,b
λ
2
n∑
i,j=1
vivjK(xi,xj) +
1
n
n∑
i=1
rˆi
π(ai,xi)
T
(
ai
( n∑
j=1
vjK(xi,xj) + b
))
. (15)
Following a similar derivation to that used in the previous section, the convex subproblem
at the (t+ 1)’th iteration of the d.c. algorithm is as follows,
min
v,b
λ
2
n∑
i,j=1
vivjK(xi,xj)+
1
n
n∑
i=1
[
φ1(ui)I(rˆi > 0)+φ0(ui)I(rˆi < 0)
] |rˆi|
π(ai,xi)
+
n∑
i=1
β
(t)
i ui,
where ui = ai
(∑n
j=1 vjK(xi,xj)+b
)
. After solving the subproblem by L-BFGS, we update
β(t+1) by (12). The procedure is repeated until β converges. When we obtain the solution
(vˆ, bˆ), the decision function is fˆ(x) =
∑n
j=1 vˆjK(x,xj) + bˆ. Note that if we choose a
linear kernel K(x,z) = xTz, the obtained rule reduces to the previous linear rule. The
most widely used nonlinear kernel in practice is the Gaussian Radial Basis Function (RBF)
kernel, that is,
Kσ(x,z) = exp
(
− σ2||x− z||2
)
,
where σ > 0 is a free parameter whose inverse 1/σ is called the width of Kσ.
2.4 A general framework for Residual Weighted Learning
We have proposed a method to identify the optimal ITR for continuous outcomes. However,
in clinical practice, the endpoint outcome could also be binary, count, or rate. In this
section, we provide a general framework to deal with all these types of outcomes.
The procedure is described as follows. First, estimate the conditional expected outcomes
given clinical covariates X, Eˆ
(
R
2π(A,X)
∣∣X), by an appropriate regression model. It is
equivalent to fitting a weighted regression model, in which each subject is weighted by
1
2π(A,X) . Second, we calculate the estimated residual rˆi by comparing the observed outcome
and expected outcome estimated in the first step. If the observed outcome is better than
the expected one, the estimated residual rˆi is positive, otherwise it is negative. Specifically,
if larger values of R are more desirable, as with our assumption for continuous outcomes,
rˆi = ri − Eˆ
(
R
2π(A,X)
∣∣X = xi); if smaller values of R are preferred, e.g. the number of
adverse events, then rˆi = Eˆ
(
R
2π(A,X)
∣∣X = xi) − ri. Third, identify the decision function
fˆ(x) by using the estimated rˆi in RWL.
The underlying idea is simple. Generally, the outcome R is a random variable depend-
ing on X and A. We estimate common effects of X by ignoring the treatment assignment
A, and then all information on the heterogeneous treatment effects is contained in the
residuals. As demonstrated previously, the benefits from using residuals include stabilizing
the variance and controlling the treatment matching factor, both of which have a positive
impact on finite sample performance. In previous sections, we discussed RWL for continu-
ous outcomes in detail. We will provide two additional examples to illustrate the general
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framework.
The first example is for binary outcomes, i.e. R ∈ {0, 1}. Assume that R = 1 is
desirable. We may fit a weighted main effects logistic regression model,
E(R|X) = exp(β0 +X
Tβ)
1 + exp(β0 +XTβ)
.
The estimates βˆ0 and βˆ can be obtained numerically by statistical software, for example,
the glm function in R. The residual rˆi is ri− exp(βˆ0+X
T βˆ)
1+exp(βˆ0+XT βˆ)
. Then we estimate the optimal
ITR by RWL.
The second is for count/rate outcomes. We use the pulmonary exacerbation (PE)
outcome of the cystic fibrosis data in Section 6 as an example. The outcome is the number of
PEs during the study, and it is a rate variable. The observed data areDn = {xi, ai, ri, ti}ni=1,
where ri is the number of PEs in the duration ti. We treat the count ri as the outcome,
and (xi, ti) as clinical covariates. We may fit a weighted main effects Poisson regression
model,
log (E(R|X, T )) = β0 +XTβ + log(T ).
Since fewer PEs are desirable, we compute rˆi as exp
(
βˆ0 + x
T
i βˆ + log(ti)
)
− ri, which is the
opposite of the raw residual in generalized linear models.
3 Theoretical Properties
In this section, we establish theoretical results for RWL. To the end, we assume that a
sample Dn = {xi, ai, ri}ni=1, is independently drawn from a probability measure P on
X ×A×M, where X ⊂ Rp is compact, and M = [−M,M ] ⊂ R. For any ITR d : X → A,
the risk is defined as
R(d) = E
[
R
π(A,X)
I(A 6= d(X))
]
.
The ITR that minimizes the risk is the Bayes rule d∗ = argmindR(d), and the correspond-
ing risk R∗ = R(d∗) is the Bayes risk. Recall that the Bayes rule is d∗(x) = sign(E(R|X =
x, A = 1)− E(R|X = x, A = −1)).
In RWL, we substitute the 0-1 loss I(A 6= sign(f(X))) by the smoothed ramp loss,
T (Af(X)). Accordingly, we define the T -risk as
RT,g(f) = E
[
R− g(X)
π(A,X)
T (Af(X))
]
,
and, similarly, the minimal T -risk as R∗T,g = inff RT,g(f) and f∗T,g = argminf RT,g(f).
In the theoretical analysis, we do not require g to be a regression fit of R. g can be
any arbitrary measurable function. We may further assume that (R − g(X))/π(A,X) is
bounded almost surely.
The performance of an ITR associated with a real-valued function f is measured by the
excess risk R(sign(f))−R∗. In terms of the value function, we note that the excess risk is
just V(d∗)− V(sign(f)). Similarly, we define the excess T -risk as RT,g(f)−R∗T,g.
Let fDn,λn ∈ HK + {1}, i.e. fDn,λn = hDn,λn + bDn,λn where hDn,λn ∈ HK and bDn,λn ∈
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R, be a global minimizer of the following optimization problem:
min
f=h+b∈HK+{1}
λn
2
||h||2K +
1
n
n∑
i=1
ri − g(xi)
π(ai,xi)
T
(
aif(xi))
)
.
Here we suppress g from the notation of fDn,λn , hDn,λn and bDn,λn .
The purpose of the theoretical analysis is to estimate the excess risk R(sign(fDn,λn))−
R∗ as the sample size n tends to infinity. Convergence rates will be derived under the choice
of the parameter λn and conditions on the distribution P .
3.1 Fisher Consistency
We establish Fisher consistency of the decision function based on the smoothed ramp loss.
Specifically, the following result holds:
Theorem 3.1. For any measurable function f , if f∗T,g minimizes T-risk RT,g(f), then the
Bayes rule d∗(x) = sign(f∗T,g(x)) for all x such that E(R|X = x, A = 1) 6= E(R|X =
x, A = −1). Furthermore, RT,g(d∗) = R∗T,g.
The proof is provided in Appendix. This theorem shows the validity of using the
smoothed ramp loss as a surrogate loss in RWL.
3.2 Excess Risk
The following result establishes the relationship between the excess risk and excess T -risk.
The proof can be found in Appendix.
Theorem 3.2. For any measurable f : X → R and any probability distribution for
(X, A,R),
R(sign(f))−R∗ ≤ RT,g(f)−R∗T,g.
This theorem shows that for any decision function f , the excess risk of f under the 0-1
loss is no larger than the excess risk of f under the smoothed ramp loss. It implies that if
we obtain f by approximately minimizing RT,g(f) so that the excess T -risk is small, then
the risk of f is close to the Bayes risk. In the next two sections, we investigate properties
of fDn,λn through the excess T -risk.
3.3 Universal Consistency
In the literature of machine learning, a classification rule is called universally consistent if
its expected error probability converges in probability to the Bayes error probability for
all distributions underlying the data (Devroye et al. 1996). We extend this concept to
ITRs. Precisely, given a sequence Dn of training data, an ITR dn is said to be universally
consistent if
lim
n→∞R(dn) = R
∗
holds in probability for all probability measures P on X ×A×M. In this section, we will
establish universal consistency of the rule dDn,λn = sign(fDn,λn). Before proceeding to the
main result, we introduce some preliminary background on RKHSs, which is essential for
our work.
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Let K be a kernel, and HK be its associated RKHS. We often use the quantity
CK = sup
x∈X
√
K(x,x).
In this article, we assume CK is finite. For the Gaussian RBF kernel, CK = 1. The
assumption also holds for the linear kernel when X ⊂ Rp is compact. By the reproducing
property, it is easy to see that ||f ||∞ ≤ CK ||f ||K for any f ∈ HK . A continuous kernel
K on a compact metric space X is called universal if its associated RKHS HK is dense
in C(X ), i.e., for every function g ∈ C(X ) and all ǫ > 0 there exists an f ∈ HK such
that ||f − g||∞ < ǫ (Steinwart and Christmann 2008, Definition 4.52). C(X ) is the space
of all continuous functions f : X → R on the compact metric space X endowed with the
usual supremum norm. The widely used Gaussian RBF kernel is an example of a universal
kernel.
We are ready to present the main result of this section. The following theorem shows
the convergence of the T -risk on the sample dependent function fDn,λn . We apply empirical
process techniques to show consistency. The proof is provided in Appendix.
Theorem 3.3. Assume that we choose a sequence λn > 0 such that λn → 0 and nλn →∞.
For a measurable function g, assume that |R−g(X)|π(A,X) ≤ M0 almost surely. Then for any
distribution P for (X, A,R), we have that in probability,
lim
n→∞RT,g(fDn,λn) = inff∈HK+{1}RT,g(f).
By Theorem 3.1, the Bayes rule d∗ minimizes the T -risk RT,g(f). Universal consis-
tency follows if inff∈HK+{1}RT,g(f) = R∗T,g by Theorem 3.2. That is, d∗ needs to be
approximated by functions in the space HK + {1}. Clearly, this is not always true. A
counterexample is when K is linear.
Let µ be the marginal distribution of X. Clearly, the rule d∗ is measurable with respect
to µ. Recall that a probability measure is regular if it is defined on the Borel sets. By
Lusin’s theorem, a measurable function can be approximated by a continuous function
when µ is regular (Rudin 1987, Theorem 2.24). Thus the RKHS HK of a universal kernel
K is rich enough to provide arbitrarily accurate decision rules for all distributions. The
finding is summarized in the following universal approximation lemma. The rigorous proof
is provided in Appendix.
Lemma 3.4. Let K be a universal kernel, and HK be the associated RKHS. For all distri-
butions P with regular marginal distribution µ on X, we have
inf
f∈HK+{1}
RT,g(f) = R∗T,g.
This immediately leads to universal consistency of RWL with a universal kernel.
Proposition 3.5. Let K be a universal kernel, and HK be the associated RKHS. Assume
that we choose a sequence λn > 0 such that λn → 0 and nλn → ∞. For a measurable
function g, assume that |R−g(X)|π(A,X) ≤ M0 almost surely. Then for any distribution P for
(X, A,R) with regular marginal distribution on X, we have that in probability,
lim
n→∞R(sign(fDn,λn)) = R
∗.
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3.4 Convergence Rate
A consistent rule guarantees that by increasing the amount of data the rule can eventually
learn the optimal decision with high probability. The next natural question is whether there
are rules dn with R(dn) tending to the Bayes risk R∗ at a specified rate for all distributions.
Unfortunately, this is impossible as shown in the following theorem. The proof follows the
arguments in Devroye et al. (1996, Theorem 7.2), which states in the classification problem
the rate of convergence of any particular rule to the Bayes risk may be arbitrarily slow. We
provide the outline of the proof in Appendix.
Theorem 3.6. Assume there are infinite distinct points in X . Let {cn} be a sequence of
positive numbers converging to zero with 116 ≥ c1 ≥ c2 ≥ · · · . For every sequence dn of
ITRs, there exists a distribution of (X, A,R) on X ×A×M such that
R(dn)−R∗ ≥ 2Mcn.
This is a generic result, and applies to any algorithm for ITRs. It implies that rate of
convergence studies for particular rules must necessarily be accompanied by conditions on
(X, A,R). Before moving back to RWL, we introduce the following quantity:
A(λ) = inf
h∈HK ,b∈R
λ
2
||h||2K +RT,g(h+ b)−R∗T,g.
The term A(λ) describes how well the infinite-sample regularized T -risk λ2 ||h||2K+RT,g(h+b)
approximates the optimal T -risk R∗T,g. A similar quantity is called the approximation error
function in the literature of learning theory (Steinwart and Christmann 2008, Definition
5.14). Since A(λ) is an infimum of affine linear functions, A(λ) is continuous. Thus
lim
λ→0
A(λ) = inf
h∈HK ,b∈R
RT,g(h+ b)−R∗T,g.
By Lemma 3.4, for a universal kernel K, limλ→0A(λ) = 0.
In order to establish the convergence rate, let us additionally assume that there exist
constants c > 0 and β ∈ (0, 1] such that
A(λ) ≤ cλβ , ∀λ > 0. (16)
The assumption is standard in the literature of learning theory (Steinwart and Christmann
2008, p. 229). The following theorem is the main result in this section. This theorem
is proved in Appendix using techniques of concentration inequalities developed in Bartlett
and Mendelson (2002).
Theorem 3.7. For any distribution P for (X, A,R) that satisfies the approximation error
assumption (16), take λn = n
− 1
2β+1 . For a measurable function g, assume that |R−g(X)|π(A,X) ≤
M0 almost surely. Then with probability at least 1− δ,
R(sign(fDn,λn))−R∗ ≤ c˜
√
log(4/δ)n
− β
2β+1 ,
where the constant c˜ is independent of δ and n, and c˜ decreases as M0 decreases.
The resulting rate depends on the polynomial decay rate β of the approximation error,
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and the optimal rate is about n−1/3 when β approaches 1. Theorem 3.7 also implies that
even when the sample size n is fixed, an appropriately chosen g with a small bound M0
would improve performance. It is easy to verify that g∗ in (5) is the function g that
minimizes E
(
(R−g(X))2
π(A,X)
)
. So when we choose g∗ as in RWL, we may possibly obtain a
smaller M0, as shown in Figure 1.
We are particularly interested in the Gaussian RBF kernel since it is widely used and is
universal. It is important to understand the approximation error assumption (16) for the
Gaussian RBF kernel. We first introduce the following “geometric noise” assumption for
P on (X, A,R) (Steinwart and Scovel 2007). Let
δ(x) = E(R|X = x, A = 1)− E(R|X = x, A = −1).
Define X+ = {x ∈ X : δ(x) > 0}, X− = {x ∈ X : δ(x) < 0}, and X 0 = {x ∈ X : δ(x) = 0}.
Now we define a distance function x 7→ τx by
τx =


d˜(x,X 0 ∪ X+) if x ∈ X−,
d˜(x,X 0 ∪ X−) if x ∈ X+,
0 if x ∈ X 0,
where d˜(x, A) denotes the distance of x to a set A with respect to the Euclidean norm.
Now we present the geometric noise condition for distributions.
Definition 3.8. Let X ⊂ Rp be compact and P be a probability measure of (X, A,R) on
X × A×M. We say that P has geometric noise exponent q > 0 if there exists a constant
C > 0 such that ∫
X
exp
(
−τ
2
x
t
)
|δ(x)|µ(dx) ≤ Ctqp/2, t > 0, (17)
where µ is the marginal measure on X.
The integral condition (17) describes the concentration of the measure |δ(x)|dµ near
the decision boundary in the sense that the less the measure is concentrated in this region
the larger the geometric noise exponent can be chosen. The following lemma shows that
the geometric noise condition can be used to guarantee the approximation error assumption
(16) when the parameter σ of the Gaussian RBF kernel Kσ is appropriately chosen.
Lemma 3.9. Let X be the closed unit ball of the Euclidean space Rp, and P be a distribution
on X ×A×M that has geometric noise exponent 0 < q <∞ with constant C in (17). Let
σ = λ
− 1
(q+1)p . Then for the Gaussian RBF kernel Kσ, there is a constant c > 0 depending
only on the dimension p, the geometric noise exponent q and constant C, such that for all
λ > 0 we have
A(λ) ≤ cλq/(q+1).
The proof provided in Appendix follows the idea from Theorem 2.7 in Steinwart and
Scovel (2007) by replacing their 2η(x) − 1 with δ(x). The key point is the following in-
equality, for all measurable f ,
RT,g(f)−R∗T,g ≤ 2E(|δ(x)| · |f − d∗|),
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which is the counterpart of Equation (24) in Steinwart and Scovel (2007).
Now we are ready to present the convergence rate of RWL with Gaussian RBF kernel
by combining Theorem 3.7 and Lemma 3.9:
Proposition 3.10. Let X be the closed unit ball of the Euclidean space Rp, and P be a
distribution on X ×A×M that has geometric noise exponent 0 < q <∞ with constant C
in (17). For a measurable function g, assume that |R−g(X)|π(A,X) ≤M0 almost surely. Consider
a Gaussian RBF kernel Kσn . Take λn = n
− q
3q+1 and σn = λ
− 1
(q+1)p
n . Then with probability
at least 1− δ,
R(sign(fDn,λn))−R∗ ≤ c˜
√
log(4/δ)n−
q
3q+1 ,
where the constant c˜ is independent of δ and n, and c˜ decreases as M0 decreases.
The optimal rate for the risk is about n−1/3 when the geometric noise exponent q is
sufficiently large. A better rate may be achieved by using techniques in Steinwart and
Scovel (2007), but it is beyond the scope of this work.
4 Variable selection for RWL
Variable selection is an important area in modern statistical research. Gunter et al. (2011)
distinguished prescriptive covariates from predictive covariates. The latter refers to covari-
ates which are related to the prediction of outcomes, and the former refers to covariates
which help to prescribe optimal ITRs. Clearly, prescriptive covariates are predictive too.
In practice, a large number of clinical covariates are often available for estimating optimal
ITRs. However, many of them might not be prescriptive. Thus careful variable selection
could lead to better performance.
4.1 Variable selection for linear RWL
There is a vast body of literature on variable selection for linear classification in statistical
learning. For instance, Zhu et al. (2003) and Fung and Mangasarian (2004) investigated
the support vector machine (SVM) using the ℓ1-norm penalty (Tibshirani 1994). Wang
et al. (2008) applied the elastic-net penalty (Zou and Hastie 2005) for variable selection
with an SVM-like method. In this article, we replace the ℓ2-norm penalty in RWL with the
elastic-net penalty,
λ1||w||1 + λ2
2
wTw,
where ||w||1 =
∑p
j=1 |wj| is the ℓ1-norm. As a hybrid of the ℓ1-norm and ℓ2-norm penal-
ties, the elastic-net penalty retains the variable selection features of the ℓ1-norm penalty,
and tends to provide similar estimated coefficients for highly correlated variables, i.e. the
grouping effect, as the ℓ2-norm penalty does. Hence, highly correlated variables are selected
or removed together.
The elastic-net penalized linear RWL aims to minimize
λ1||w||1 + λ2
2
wTw +
1
n
n∑
i=1
rˆi
π(ai,xi)
T
(
ai(w
Txi + b)
)
,
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where λ1(> 0) and λ2(≥ 0) are regularization parameters. We still apply the d.c. algorithm
to solve the above optimization problem. Following a similar decomposition, the convex
subproblem at the (t+ 1)’th iteration of the d.c. algorithm is as follows,
min
w,b
λ1||w||1 + λ2
2
wTw +
1
n
n∑
i=1
[
φ1(ui)I(rˆi > 0) + φ0(ui)I(rˆi < 0)
] |rˆi|
π(ai,xi)
+
n∑
i=1
β
(t)
i ui,
(18)
where ui = ai(w
Txi + b), and β
(t)
i is computed by (12). The objective function is a sum
of a smooth function and a non-smooth ℓ1-norm penalty. Since L-BFGS can only deal
with smooth objective functions, it may not work here. Instead we use projected scaled
sub-gradient (PSS) algorithms (Schmidt 2010), which are extensions of L-BFGS to the
case of optimizing a smooth function with an ℓ1-norm penalty. Several PSS algorithms
are proposed in Schmidt (2010). Among them, the Gafni-Bertseka variant is particularly
effective for our purpose. After solving the subproblem, we update β
(t+1)
i by (12). The
procedure is repeated until β converges. The obtained decision function is fˆ(x) = wˆTx+ bˆ,
and thus the estimated optimal ITR is the sign of fˆ(x).
4.2 Variable selection for RWL with nonlinear kernels
Many researchers have noticed that nonlinear kernel methods may perform poorly when
there are irrelevant covariates presented in the data (Weston et al. 2000; Grandvalet and
Canu 2002; Lin and Zhang 2006; Lafferty and Wasserman 2008). For optimal treatment
regimes, we may suffer a similar problem when using a nonlinear kernel. For the Gaussian
RBF kernel, we assume that the geometric noise condition in Definition 3.8 is satisfied with
exponent q. When several additional non-descriptive covariates are included in the data,
the geometric noise exponent is decreased according to (17), and hence so is the convergence
rate in Proposition 3.10. The presence of non-descriptive covariates thus can deteriorate
the performance of RWL.
The variable selection approach proposed in this section is inspired by the KNIFE
algorithm (Allen 2013), where a set of scaling factors on the covariates are employed to form
a regularized loss function. The idea of scaling covariates within the kernel has appeared
in several methods from the machine learning community (Weston et al. 2000; Grandvalet
and Canu 2002; Rakotomamonjy 2003; Argyriou et al. 2006).
We take the Gaussian RBF kernel as an example. Define the covariates-scaled Gaussian
RBF kernel,
Kη(x,z) = exp

− p∑
j=1
ηj(xj − zj)2

 ,
where η = (η1, · · · , ηp)T ≥ 0. Here each covariate xj is scaled by √ηj . Setting ηj = 0 is
equivalent to discarding the j’th covariate. The hyperparameter σ in the original Gaussian
RBF kernel is absorbed to the scaling factors. Similar with KNIFE, we seek (vˆ, bˆ, ηˆ) to
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minimize the following optimization problem:
min
v,b,η
λ1||η||1 + λ2
2
n∑
i,j=1
vivjKη(xi,xj)
+
1
n
n∑
i=1
rˆi
π(ai,xi)
T
(
ai
( n∑
j=1
vjKη(xi,xj) + b
))
, (19)
subject to η ≥ 0,
where λ1(> 0) and λ2(> 0) are regularization parameters. Compared with previous non-
linear RWL optimization problem in (15), (19) has an ℓ1-norm penalty on scaling factors.
The objective function is singular at η = 0 due to nonnegativity of scaling factors. So (19)
may produce zero solutions for some of the η, and hence performs variable selection.
We adopt a similar decomposition trick that has been used several times before. The
subproblem at the (t+ 1)’th iteration is
min
v,b,η
λ1||η||1 + λ2
2
n∑
i,j=1
vivjKη(xi,xj)
+
1
n
n∑
i=1
[
φ1(ui)I(rˆi > 0) + φ0(ui)I(rˆi < 0)
] |rˆi|
π(ai,xi)
+
n∑
i=1
β
(t)
i ui,(20)
subject to η ≥ 0,
where ui = ai
(∑n
j=1 vjKη(xi,xj) + b
)
, and β
(t)
i is computed by (12). Recall that the d.c.
algorithm is a special case of the Majorize-Minimization (MM) algorithm. Although with
the covariate-scaled kernel the subproblem is nonconvex, we still apply a similar iterative
procedure as in the d.c. algorithm, i.e. solving a sequence of subproblems (20), but based
on the MM algorithm. The subproblem (20) is a smooth optimization problem with box
constraints. In this article, we use L-BFGS-B (Byrd et al. 1995; Morales and Nocedal
2011), which extends L-BFGS to handle simple box constraints on variables. After solving
the subproblem (20), we update ui and β. The procedure is repeated until convergence.
Then the obtained decision function is fˆ(x) =
∑n
i=1 vˆiKηˆ(xi,x)+ bˆ, and thus the estimated
optimal ITR is the sign of fˆ(x). The covariates with nonzero scaling factors ηˆ are identified
to be important in estimating ITRs.
This variable selection technique can be applied to other nonlinear kernels, such as the
polynomial kernel, and even to the linear kernel. However for the linear kernel, we recom-
mend the approach in the prior section, where the subproblem (18) is a convex optimization
problem with p + 1 variables. Note that the subproblem (20) in this section is nonconvex
even for the linear kernel, and there are n + p + 1 variables for the optimization problem.
This is much more challenging.
5 Simulation studies
We carried out extensive simulation studies to investigate finite sample performance of the
proposed RWL methods.
We first evaluated the performance of RWL methods with low-dimensional covariates.
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In the simulations, we generated 5-dimensional vectors of clinical covariates x1, · · · , x5, con-
sisting of independent uniform random variables U(−1, 1). The treatment A was generated
from {−1, 1} independently of X with P (A = 1) = 0.5. That is, π(a,x) = 0.5 for all a
and x. The response R was normally distributed with mean Q0 = µ0(x) + δ0(x) · a and
standard deviation 1, where µ0(x) is the common effect for clinical covariates, and δ0(x) ·a
is the interaction between treatment and clinical covariates. We considered five scenarios
with different choices of µ0(x) and δ0(x):
(0) µ0(x) = 1 + x1 + x2 + 2x3 + 0.5x4; δ0(x) = 0.4(x2 − 0.25x21 − 1).
(1) µ0(x) = 1 + x1 + x2 + 2x3 + 0.5x4; δ0(x) = 1.8(0.3 − x1 − x2).
(2) µ0(x) = 1 + x1 + x2 + 2x3 + 0.5x4; δ0(x) = 1.3(x2 − 2x21 + 0.3).
(3) µ0(x) = 1 + x
2
1 + x
2
2 + 2x
2
3 + 0.5x
2
4; δ0(x) = 3.8(0.8 − x21 − x22).
(4) µ0(x) = 1 + x
2
1 + x
2
2 + 2x
2
3; δ0(x) = 10(1 − x21 − x22)(x21 + x22 − 0.2).
Scenario 0 is similar with the second scenario in Zhao et al. (2012). When x2 is restricted
to [−1, 1], the treatment arm −1 is always better than the treatment arm 1 on average.
Thus the true optimal ITR in Scenario 0 is to assign all subjects to arm −1. The decision
boundaries for the remaining four scenarios are determined by x1 and x2 only. The scenarios
have different decision boundaries in truth. The decision boundary is a line in Scenario 1, a
parabola in Scenario 2, a circle in Scenario 3, and a ring in Scenario 4. Their true optimal
ITRs are illustrated in Figure 3. It is unclear how often a circle or ring boundary structure
will occur in practice, although general nonlinear boundaries are likely to arise frequently.
The purpose of including these in the simulations is to verify that the proposed approach
can handle even the most difficult boundary structures. The coefficients in Scenarios 0 ∼ 3
were chosen to reflect a medium effect size according to Cohen’s d index (Cohen 1988); and
the coefficients in Scenario 4 reflect a small effect size. The Cohen’s d index is defined as
the standardized difference in mean responses between two treatment arms, that is,
es =
|E(R|A = 1)− E(R|A = −1)|√
[V ar(R|A = 1) + V ar(R|A = −1)]/2 .
We compared the performance of the following five methods:
(1) The proposed RWL using the Gaussian RBF kernel (RWL-Gaussian). Residuals were
estimated by a linear main effects model.
(2) The proposed RWL using the linear kernel (RWL-Linear). Residuals were estimated
by a linear main effects model.
(3) OWL proposed in Zhao et al. (2012) using the Gaussian RBF kernel (OWL-Gaussian).
(4) OWL using the linear kernel (OWL-Linear).
(5) ℓ1-PLS proposed by Qian and Murphy (2011).
The OWL methods were reviewed in the method section. Since the OWL methods can
only handle nonnegative outcomes, we subtracted min{ri} from all outcome responses.
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Figure 3: True optimal ITRs in simulation studies. For subjects in the shade area, the best
treatment is 1; for subjects in the white area, the best treatment is −1.
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This is essentially the approach used in Zhao et al. (2012) [personal communication].
In the simulation studies, ℓ1-PLS approximated E(R|X, A) using the basis function set
(1,X, A,XA), and applied LASSO (Tibshirani 1994) for variable selection. The optimal
ITR was determined by the sign of the difference between the estimated E(R|X, A = 1)
and E(R|X, A = −1).
For each scenario, we considered two sample sizes for training datasets: n = 100 and
n = 400, and repeated the simulation 500 times. All five methods had at least one tun-
ing parameter. For example, there was one tuning parameter, λ, in RWL-linear; and
two tuning parameters, λ and σ in RWL-Gaussian. In the simulations, we applied a 10-
fold cross-validation procedure to tune parameters. For RWL-Linear, we searched over a
pre-specified finite set of λ’s to select the best one maximizing the average of estimated
values from validation data; while for RWL-Gaussian, we searched over a pre-specified fi-
nite set of (λ, σ)’s to select the best pair. The selection of tuning parameters in ℓ1-PLS
and OWL followed similarly. In the comparisons, the performances of five methods were
evaluated by two criteria: the first criterion is the value function under the estimated op-
timal ITR when we applied to an independent and large test dataset; the second criterion
is the misclassification error rate of the estimated optimal ITR from the true optimal ITR
on the large test dataset. Specifically, a test set with 10,000 observations was simulated
to assess the performance. The estimated value function under any ITR d is given by
P
∗
n[RI(A = d(X))/π(A,X)]/P
∗
n [I(A = d(X))/π(A,X)] (Murphy 2005), where P
∗
n denotes
the empirical average using the test data; the misclassification rate under any ITR d is
given by P∗n[I(d(X) 6= d∗(X))], where d∗ is the true optimal ITR which is known when
generating the simulated data.
The simulation results are presented in Table 1. We report the mean and standard
deviation of value functions and misclassification rates over 500 replications. In Scenario 0,
the true optimal ITR would assign all subjects to treatment arm −1. When the sample size
was small (n = 100), ℓ1-PLS, OWL-Linear and RWL-Linear showed similar performance,
while OWL-Gaussian and RWL-Gaussian were slightly worse. Note that when x2 can go
beyond 1, the heterogeneous treatment effect does exist with non-linear (parabola) decision
boundary. The deteriorated performance of OWL-Gaussian and RWL-Gaussian may be
due to unexpected extrapolation. When the sample size was large (n = 400), all methods
performed similarly, and assigned almost all subjects to arm −1. Scenario 1 was a linear
example. The model specification in ℓ1-PLS was correct, and this method performed very
well. The proposed RWL methods, with either the linear kernel or the Gaussian RBF
kernel, yielded similar performance with ℓ1-PLS, and were much better than OWL methods.
Another advantage of using RWL versus OWL was also reflected by a smaller variance in
value functions. The idea of using residuals instead of the original outcomes is able to
stabilize the variance, as we discussed in the method section.
The conditional mean outcomes and decision boundaries in the remaining three scenarios
were nonlinear. ℓ1-PLS, RWL-Linear, and OWL-Linear were misspecified, and hence they
did not perform very well in these three scenarios. We focus on the comparison between
RWL-Gaussian and OWL-Gaussian. These two methods equipped with the Gaussian RBF
kernel should have the ability to capture the nonlinear structure of decision boundaries.
In Scenarios 2 and 3, RWL-Gaussian outperformed OWL-Gaussian in terms of achieving
higher values and smaller variances. It was challenging to find the optimal ITR in Scenario
4 since the decision boundary was complicated and the effective size was small. When
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the sample size was small (n = 100), the performance of RWL-Gaussian was only slightly
better than that of OWL-Gaussian, but with larger variance. It might be too hard to
learn the complicated decision boundary from the limited sample. However, when the
sample size increased, RWL-Gaussian showed significantly better performance than other
methods. The excellent performance of RWL-Gaussian confirms its power in finding the
optimal ITR. Although using the Gaussian RBF kernel, the performance of OWL-Gaussian
was not comparable with that of RWL-Gaussian. In Scenario 2, OWL-Gaussian performed
even worse than ℓ1-PLS and RWL-Linear, both of which can only detect linear boundaries.
While in Scenario 4, OWL-Gaussian gave similar performance as OWL-Linear. Zhao et al.
(2012) also reported similar finding in their simulation studies that there are no large
differences in the performance between OWL-Linear and OWL-Gaussian.
As we demonstrated in Section 2.2, OWL methods tend to favor the treatment assign-
ments that subjects actually received, and this behavior deteriorates finite sample perfor-
mance. We calculated treatment matching factors of these five methods on the training
data. They are shown in Table 2. We expect the treatment matching factor to be close
to 1. However, the treatment matching factors for OWL methods were greater than 1.
OWL-Gaussian achieved the largest treatment matching factors, especially when the sam-
ple size was small. This may partially explain why OWL-Gaussian may not outperform
OWL-Linear even when the decision boundary is nonlinear. Whereas for RWL methods,
the treatment matching factors were close to 1. By appropriately controlling the treatment
matching factors, the aim of RWL methods is to maximize the estimate in (8), and hence
to improve finite sample performance.
We applied a linear main effects model to estimate residuals. The model was correctly
specified for Scenarios 0, 1 and 2, and misspecified for Scenarios 3 and 4. However, the
superior performance of RWL methods in Scenarios 3 and 4 demonstrates the robustness of
our methods to residual estimates. We also considered a null model, which was misspecified
for all scenarios, to estimate residuals. The results were only slightly worse than those shown
in Table 1 for Scenarios 1 and 2 when n = 100, and other scenarios were similar especially
when the sample size increased [results not shown].
We then evaluated the performance of RWL methods with moderate-dimensional clinical
covariates. We adopted the same data generating procedure as in the above five scenarios
except that the dimension of clinical covariates was increased from 5 to 50 by adding 45 in-
dependent uniform random variables U(−1, 1). Thus among all these 50 clinical covariates,
only x1 and x2 are attributed to the decision boundaries for Scenarios 1 ∼ 4. We repeated
the simulations, and the results are shown in Table 3. In Scenario 0, all methods performed
similar, and assigned almost all subjects to the treatment arm −1 when the sample size
was large (n = 400). In Scenario 1, ℓ1-PLS performed very well because of correct model
specification and inside variable selection techniques. Although RWL methods showed bet-
ter performance than OWL methods, they were not comparable to ℓ1-PLS. The decision
boundaries in Scenarios 2 ∼ 4 are nonlinear. Both RWL and OWL failed to detect the
decision boundaries in these scenarios. They produced similar performance with either the
linear kernel or Gaussian RBF kernel. RWL and OWL methods with Gaussian RBF kernel
may perform particularly poorly when many non-descriptive covariates are present.
We tested the performance of variable selection approaches described in Section 4 for
the linear kernel and Gaussian RBF kernel. They are called RWL-VS-Linear and RWL-VS-
Gaussian, respectively, in this article. There were two tuning parameters, λ1 and λ2, for
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Table 1: Mean (std) of empirical value functions and misclassification rates evaluated on
independent test data for 5 simulation scenarios with 5 covariates. The best value function
and minimal misclassification rate for each scenario and sample size combination are in
bold.
n = 100 n = 400
Value Misclassification Value Misclassification
Scenario 0 (Optimal value 1.43)
ℓ1-PLS 1.41 (0.07) 0.05 (0.10) 1.42 (0.01) 0.02 (0.04)
OWL-Linear 1.39 (0.11) 0.07 (0.14) 1.43 (0.02) 0.01 (0.04)
OWL-Gaussian 1.33 (0.15) 0.13 (0.18) 1.41 (0.05) 0.03 (0.08)
RWL-Linear 1.40 (0.05) 0.06 (0.09) 1.42 (0.02) 0.03 (0.05)
RWL-Gaussian 1.34 (0.10) 0.13 (0.13) 1.40 (0.04) 0.07 (0.07)
Scenario 1 (Optimal value 2.25)
ℓ1-PLS 2.22 (0.03) 0.06 (0.04) 2.24 (0.02) 0.03 (0.03)
OWL-Linear 1.91 (0.22) 0.23 (0.09) 2.08 (0.14) 0.16 (0.06)
OWL-Gaussian 1.88 (0.24) 0.24 (0.09) 2.08 (0.12) 0.16 (0.06)
RWL-Linear 2.19 (0.04) 0.09 (0.04) 2.23 (0.01) 0.05 (0.02)
RWL-Gaussian 2.17 (0.06) 0.11 (0.04) 2.22 (0.02) 0.05 (0.02)
Scenario 2 (Optimal value 1.96)
ℓ1-PLS 1.71 (0.07) 0.24 (0.04) 1.75 (0.01) 0.22 (0.01)
OWL-Linear 1.51 (0.12) 0.32 (0.05) 1.59 (0.10) 0.29 (0.06)
OWL-Gaussian 1.49 (0.15) 0.33 (0.06) 1.63 (0.11) 0.26 (0.05)
RWL-Linear 1.66 (0.08) 0.26 (0.04) 1.74 (0.03) 0.23 (0.02)
RWL-Gaussian 1.75 (0.09) 0.20 (0.05) 1.90 (0.03) 0.10 (0.03)
Scenario 3 (Optimal value 3.88)
ℓ1-PLS 3.00 (0.11) 0.38 (0.03) 3.03 (0.04) 0.37 (0.01)
OWL-Linear 2.98 (0.10) 0.38 (0.03) 3.01 (0.02) 0.38 (0.01)
OWL-Gaussian 3.21 (0.18) 0.32 (0.05) 3.56 (0.12) 0.22 (0.04)
RWL-Linear 3.15 (0.13) 0.34 (0.03) 3.28 (0.04) 0.31 (0.01)
RWL-Gaussian 3.62 (0.12) 0.19 (0.04) 3.82 (0.04) 0.10 (0.02)
Scenario 4 (Optimal value 3.87)
ℓ1-PLS 2.29 (0.14) 0.49 (0.08) 2.38 (0.15) 0.55 (0.08)
OWL-Linear 2.42 (0.14) 0.55 (0.08) 2.49 (0.11) 0.59 (0.06)
OWL-Gaussian 2.43 (0.15) 0.52 (0.07) 2.59 (0.15) 0.50 (0.07)
RWL-Linear 2.42 (0.14) 0.54 (0.09) 2.49 (0.10) 0.58 (0.08)
RWL-Gaussian 2.68 (0.28) 0.43 (0.08) 3.49 (0.08) 0.22 (0.03)
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Table 2: Mean (std) of treatment matching factors evaluated on the training data for 5
simulation scenarios with 5 covariates.
n = 100 n = 400
Scenario 0
ℓ1-PLS 1.00 (0.04) 1.00 (0.01)
OWL-Linear 1.03 (0.07) 1.00 (0.01)
OWL-Gaussian 1.14 (0.24) 1.02 (0.06)
RWL-Linear 1.00 (0.04) 1.00 (0.01)
RWL-Gaussian 1.00 (0.06) 1.00 (0.03)
Scenario 1
ℓ1-PLS 0.99 (0.10) 0.99 (0.05)
OWL-Linear 1.10 (0.08) 1.04 (0.04)
OWL-Gaussian 1.15 (0.13) 1.05 (0.05)
RWL-Linear 0.99 (0.09) 0.99 (0.04)
RWL-Gaussian 0.99 (0.08) 0.99 (0.04)
Scenario 2
ℓ1-PLS 1.00 (0.09) 1.00 (0.04)
OWL-Linear 1.06 (0.09) 1.03 (0.04)
OWL-Gaussian 1.18 (0.20) 1.10 (0.07)
RWL-Linear 1.00 (0.08) 1.00 (0.04)
RWL-Gaussian 1.01 (0.07) 1.00 (0.04)
Scenario 3
ℓ1-PLS 1.00 (0.05) 1.00 (0.01)
OWL-Linear 1.02 (0.06) 1.00 (0.02)
OWL-Gaussian 1.32 (0.17) 1.14 (0.05)
RWL-Linear 1.01 (0.06) 1.01 (0.04)
RWL-Gaussian 1.04 (0.06) 1.02 (0.04)
Scenario 4
ℓ1-PLS 1.00 (0.08) 1.00 (0.03)
OWL-Linear 1.07 (0.10) 1.02 (0.04)
OWL-Gaussian 1.37 (0.34) 1.27 (0.24)
RWL-Linear 1.00 (0.06) 1.00 (0.03)
RWL-Gaussian 1.00 (0.08) 1.02 (0.04)
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both approaches. We applied a 10-fold cross-validation procedure to tune parameters from
a pre-specified finite set of (λ1, λ2)’s. The simulation results are also shown in Table 3. In
Scenario 0, both RWL-VS methods showed similar performance as RWL methods. In Sce-
nario 1, both RWL-VS-Linear and RWL-VS-Gaussian improved the performance of RWL
methods. When the sample size was 400, the performance was as good as that of ℓ1-PLS.
For Scenarios 2 ∼ 4, we only present results from RWL-VS-Gaussian. When the sample
size was small (n = 100), the performance was slightly better (in Scenarios 2 and 3) than,
or similar (in scenario 4) as that of RWL-Gaussian. It is well known that large sample
sizes are needed to find interactions in models. So for similar reasons, we may expect large
samples to be necessary to find and confirm the existence of heterogeneity of treatment ef-
fects, and accurately define the decision boundary. In the simulations, when the sample size
increased, the performance of RWL-VS-Gaussian improved significantly. Variable selection
is necessary for RWL when there are many non-descriptive clinical covariates.
6 Data analysis
We applied the proposed methods to analyze data from the EPIC randomized clinical trial
(Treggiari et al. 2011). The trial was designed to determine the optimal anti-pseudomonal
treatment strategy in children with cystic fibrosis (CF) who recently acquired Pseudomonas
aeruginosa (Pa). Newly identified Pa was defined as the first lifetime documented Pa posi-
tive culture within 6 months of baseline or a Pa positive culture within 6 months of baseline
after a two-year absence of Pa culture-positivity. Other eligibility criteria have been previ-
ously reported (Treggiari et al. 2009). A total of 304 patients ages 1∼12 were randomized
in a 1:1 ratio to one of two maintenance treatment strategies: cycled therapy (treatment
with anti-pseudomonal therapy provided in quarterly cycles regardless of Pa positivity)
and culture-based therapy (treatment only in response to identification of Pa positive cul-
tures from quarterly cultures). All patients regardless of randomization strategy received
an initial course of anti-pseudomonal therapy in response to their Pa positive culture at
eligibility and proceeded with treatment according to their randomization strategy. In this
article, we considered two endpoints over the course of the 18-month study. One is the
number of Pa positive cultures from scheduled follow-up quarterly cultures, and the other
is the number of pulmonary exacerbations (PE) requiring any (intravenous, inhaled, or oral)
antibiotic use or hospitalization during the study. In the original clinical trial, there was no
significant difference between the two maintenance treatment strategies at the population
level for either the Pa outcome (p-value 0.222) or PE outcome (p-value 0.280).
We considered 10 baseline clinical covariates, including age, gender, F508del genotype,
weight, height, BMI, first documented lifetime Pa positive culture at eligibility versus
positive after a two-year history of negative cultures (neverpapos), use of antibiotics within
6 months prior to baseline (anyabxhist), Pa positive at the baseline visit versus Pa positive
within 6 months prior to baseline only (pabl), and positive versus negative baseline S.
aureus culture status (sabl). There were three levels (homozygous, heterozygous and other)
for F508del genotype. We coded genotype as two dichotomous covariates, homozygous and
heterozygous, each referenced in relation to the “othe” genotype category. Four patients did
not give consent to have their data put into the databank. We also excluded 17 patients with
missing covariate values from the analyses. The data used here consisted of 283 patients:
141 in the cycled therapy, and 142 in the culture-based therapy. Each clinical covariate was
Table 3: Mean (std) of empirical value functions and misclassification rates evaluated on
independent test data for 5 simulation scenarios with 50 covariates. The best value function
and minimal misclassification rate for each scenario and sample size combination are in bold.
n = 100 n = 400
Value Misclassification Value Misclassification
Scenario 0 (Optimal value 1.43)
ℓ1-PLS 1.34 (0.15) 0.11 (0.17) 1.42 (0.03) 0.03 (0.06)
OWL-Linear 1.36 (0.15) 0.08 (0.17) 1.43 (0.03) 0.01 (0.03)
OWL-Gaussian 1.35 (0.14) 0.10 (0.16) 1.42 (0.04) 0.01 (0.05)
RWL-Linear 1.38 (0.11) 0.07 (0.13) 1.42 (0.04) 0.03 (0.06)
RWL-Gaussian 1.34 (0.13) 0.11 (0.15) 1.40 (0.05) 0.04 (0.07)
RWL-VS-Linear 1.34 (0.11) 0.11 (0.14) 1.40 (0.04) 0.05 (0.06)
RWL-VS-Gaussian 1.33 (0.12) 0.13 (0.14) 1.41 (0.03) 0.05 (0.06)
Scenario 1 (Optimal value 2.25)
ℓ1-PLS 2.17 (0.11) 0.09 (0.06) 2.23 (0.02) 0.04 (0.03)
OWL-Linear 1.51 (0.12) 0.37 (0.03) 1.68 (0.10) 0.32 (0.03)
OWL-Gaussian 1.49 (0.13) 0.38 (0.04) 1.65 (0.11) 0.32 (0.04)
RWL-Linear 1.75 (0.14) 0.29 (0.05) 2.14 (0.03) 0.13 (0.02)
RWL-Gaussian 1.77 (0.12) 0.29 (0.04) 2.14 (0.03) 0.13 (0.02)
RWL-VS-Linear 2.05 (0.14) 0.17 (0.07) 2.22 (0.02) 0.06 (0.03)
RWL-VS-Gaussian 2.02 (0.18) 0.18 (0.08) 2.21 (0.08) 0.06 (0.04)
Scenario 2 (Optimal value 1.96)
ℓ1-PLS 1.56 (0.19) 0.30 (0.07) 1.73 (0.03) 0.23 (0.01)
OWL-Linear 1.42 (0.14) 0.37 (0.04) 1.47 (0.06) 0.35 (0.01)
OWL-Gaussian 1.40 (0.14) 0.38 (0.04) 1.47 (0.07) 0.35 (0.02)
RWL-Linear 1.42 (0.12) 0.36 (0.04) 1.60 (0.05) 0.28 (0.02)
RWL-Gaussian 1.40 (0.14) 0.36 (0.04) 1.62 (0.05) 0.28 (0.02)
RWL-VS-Gaussian 1.56 (0.15) 0.30 (0.07) 1.92 (0.06) 0.09 (0.05)
Scenario 3 (Optimal value 3.88)
ℓ1-PLS 2.90 (0.19) 0.40 (0.05) 3.00 (0.04) 0.38 (0.01)
OWL-Linear 2.96 (0.14) 0.39 (0.04) 3.00 (0.02) 0.38 (0.01)
OWL-Gaussian 2.97 (0.11) 0.39 (0.03) 3.00 (0.03) 0.38 (0.01)
RWL-Linear 2.90 (0.18) 0.40 (0.05) 3.00 (0.05) 0.38 (0.01)
RWL-Gaussian 2.88 (0.18) 0.41 (0.05) 2.96 (0.09) 0.39 (0.02)
RWL-VS-Gaussian 3.17 (0.33) 0.33 (0.09) 3.82 (0.13) 0.09 (0.05)
Scenario 4 (Optimal value 3.87)
ℓ1-PLS 2.32 (0.09) 0.49 (0.05) 2.36 (0.09) 0.52 (0.05)
OWL-Linear 2.41 (0.14) 0.55 (0.08) 2.48 (0.11) 0.59 (0.06)
OWL-Gaussian 2.43 (0.13) 0.55 (0.07) 2.47 (0.11) 0.58 (0.06)
RWL-Linear 2.38 (0.13) 0.53 (0.07) 2.44 (0.12) 0.56 (0.07)
RWL-Gaussian 2.37 (0.13) 0.53 (0.07) 2.44 (0.12) 0.56 (0.07)
RWL-VS-Gaussian 2.37 (0.12) 0.51 (0.05) 3.47 (0.47) 0.21 (0.15)
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linearly scaled to the range [−1,+1], as recommended in Hsu et al. (2003).
For the Pa-related endpoint, we used the ratio of the number of Pa negative cul-
tures to the number of Pa cultures over the follow up period as the outcome. We were
seeking an ITR to reduce the number of Pa positive cultures, so larger outcomes were
preferred. We compared seven methods: ℓ1-PLS, OWL-Linear, OWL-Gaussian, RWL-
Linear, RWL-Gaussian, RWL-VS-Linear, and RWL-VS-Gaussian. ℓ1-PLS used the basis
function set (1,X, A,XA) in the regression model. We treated the outcome as contin-
uous, and used a linear main effects model to estimate residuals for RWL methods. We
used a 10-fold cross-validation procedure to tune parameters. The estimated rule was then
used to predict the optimal treatment for each patient. The predicted treatment allocation
is shown in Table 4. To evaluate the performance of estimated rules, we again carried
out a 10-fold cross validation procedure. The data were randomly partitioned into 10
roughly equal-sized parts. We estimated the ITR on nine parts of the data using the tuned
parameters, and predicted optimal treatments on the part left out. We repeated the pro-
cedure nine more times to predict the other parts, and obtained the predicted treatment
for each patient. The first evaluation criterion was the value function, which is given by
Pn[RI(A = Pred)/π(A,X)]/Pn[I(A = Pred)/π(A,X)], where Pn denotes the empirical
average over a fold in cross validation and Pred is the predicted treatment in the cross
validation procedure. The second evaluation criterion was related to significance tests. The
test was performed when a 10-fold cross validation procedure is finished, that is, when we
had the predicted treatments for all patients. By comparing the predicted treatments with
the treatments that were actually assigned to patients, we divided patients into two groups:
those who followed the estimated optimal rule and those who did not follow the rule. We
tested the difference between the two groups using the two-sample t-test to see whether the
group that followed the estimated rule was better than the other group at the significance
level α = 0.05. The whole procedure was repeated 100 times with different fold partitions
in the cross validation. We obtained 1000 value functions and 100 p-values. The mean and
standard deviation of these value functions, the proportion of significant p-values and me-
dian of these p-values are also presented in Table 4. As reference rules, we also considered
two fixed treatment rules: assign all patients to (1) cycled therapy arm or (2) culture-based
therapy arm. We show in Table 4 their value functions from repeated 10-fold cross vali-
dation procedures and one-sided p-values from two-sample t-tests. Note that the p-values
for fixed rules were not changed during the cross validation procedure. ℓ1-PLS showed
the best performance, and identified that one covariate, baseline Pa status, is important
in estimating ITRs. The significance tests also confirmed its superior performance. Both
OWL methods failed to detect the heterogeneity of treatment effects. They assigned all
patients to the cycled therapy arm. Although the performances of RWL methods (without
variable selection) were only slightly better, on average, than those of OWL methods, they
did detect some heterogeneity across treatments. Variable selection further improved the
performance in terms of achieving higher values and better significance tests. Moreover,
both RWL-VS-Linear and RWL-VS-Gaussian selected the same covariate as ℓ1-PLS.
Our results are consistent with results from the trial suggesting that the subgroup
of patients who were Pa negative at the baseline visit (albeit positive within 6 months
of baseline to meet eligibility) may have more greatly benefited from cycled therapy to
suppress Pa positivity during the trial. However, it is important to note clinically that
further analyses of the trial data demonstrated the comparable effectiveness using culture-
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Table 4: Comparison of methods for estimating ITRs on the EPIC data with the Pa
endpoint. Higher values are better.
Predicted treatment Mean value Proportion of Median
#cycled vs #culture (std) significant p-values p-value
ℓ1-PLS 168 : 115 0.913 (0.040) 1 0.004
OWL-Linear 283 : 0 0.894 (0.054) 0 0.111
OWL-Gaussian 283 : 0 0.894 (0.054) 0 0.111
RWL-Linear 178 : 105 0.896 (0.046) 0.37 0.072
RWL-Gaussian 169 : 114 0.900 (0.045) 0.64 0.0404
RWL-VS-Linear 168 : 115 0.909 (0.044) 0.90 0.002
RWL-VS-Gaussian 168 : 115 0.907 (0.045) 0.85 0.007
Fixed rule (cycled) 283 : 0 0.894 (0.054) 0 0.111
Fixed rule (culture-based) 0 : 283 0.864 (0.054) 0 0.889
based therapy as compared to cycled therapy in reducing the overall prevalence of Pa
positive cultures at the end of the trial.
The number of PEs during the study was a rate variable. We were seeking an ITR
to lower the number of PEs, so fewer PEs were desirable. We compared several methods:
PoissonReg, ℓ1-PoissonReg, OWL-Linear, OWL-Gaussian, RWL-Linear, RWL-Gaussian,
RWL-VS-Linear, and RWL-VS-Gaussian. PoissonReg fitted a Poisson regression model
using the basis function set (1,X, A,XA), computed the predicted number of PEs for a
particular patient at each arm, and assigned the treatment with smaller prediction to this
patient. ℓ1-PoissonReg was similar with PoissonReg, but used an ℓ1 penalized term to
perform variable selection. For OWL methods, we used the opposite of individual annual
PE rate as the continuous outcome. The annual PE rate for the i-th patient is defined
as riti ∗ 365.25, where ri is the number of PEs for the i-th patient, and ti is the duration
(in days) when the i-th patient stayed in the study. For RWL methods, we used a main
effects Poisson regression model to estimate residuals, as described in Section 2.4. A 10-fold
cross-validation was used to tune parameters. The predicted treatment allocation is shown
in Table 5. A similar evaluation procedure as that for the Pa endpoint was also performed,
where we used instead the annual PE rate for the group that followed the rule as the first
evaluation criterion. The group-wise annual PE rate is given as Pn[RI(A=Pred)]
Pn[T I(A=Pred)]
∗365.25, where
R is the number of PEs, T is the duration (in days) in the study, Pn denotes the empirical
average over a fold in cross validation and Pred is the predicted treatment assignment in
the cross validation procedure. For the second criterion, a Poisson regression model was
used to test whether the group that followed the estimated rule had fewer PEs than the
other group that did not follow the estimated rule. The results are presented in Table 5.
We also considered two fixed rules as references. All RWL methods outperformed OWL and
Poisson regression methods in terms of achieving better PE rates and better significance test
results. ℓ1-PoissonReg identified three important covariates, baseline Pa status, baseline S.
aureus staus and height, for treatment assignment.
For this case, RWL-VS-Linear and RWL-VS-Gaussian did not improve performances
comparing with their counterparts without variable selection. RWL-VS-Linear did not
discard any clinical covariates. As its tuned parameter λ1 was very small, RWL-VS-Linear
gave a similar performance as RWL-Linear. The estimated rule from RWL-Linear was
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Table 5: Comparison of methods for estimating ITR on the EPIC data with the PE end-
point. Lower annual PE rates are better.
Predicted treatment Mean annual Proportion of Median
#cycled vs #culture PE rate (std) significant p-values p-value
PoissonReg 150 : 133 0.742 (0.224) 0.21 0.245
ℓ1-PoissonReg 120 : 163 0.707 (0.233) 0.55 0.042
OWL-Linear 141 : 142 0.722 (0.236) 0.27 0.123
OWL-Gaussian 140 : 143 0.714 (0.247) 0.33 0.079
RWL-Linear 105 : 178 0.673 (0.226) 0.82 0.013
RWL-Gaussian 108 : 175 0.667 (0.220) 0.90 0.008
RWL-VS-Linear 105 : 178 0.676 (0.227) 0.75 0.013
RWL-VS-Gaussian 108 : 175 0.688 (0.218) 0.69 0.024
RWL-VS-Gaussian
+ RWL-Gaussian 102 : 181 0.639 (0.220) 0.97 0.001
Fixed rule (cycled) 283 : 0 0.725 (0.245) 0 0.140
Fixed rule (culture-based) 0 : 283 0.823 (0.253) 0 0.860
determined by the following decision function F ,
F = 1.43 ∗ I(gender = female) + 0.07 ∗ age− 0.58 ∗ I(neverpapos = yes)
−1.01 ∗ I(pabl =′ +′)− 0.17 ∗ I(sabl =′ +′) + 0.02 ∗ weight + 0.01 ∗ height
−0.17 ∗ I(anyabxhist = yes) + 0.11 ∗ bmi− 0.90 ∗ I(genotype = homozygous)
−0.83 ∗ I(genotype = heterozygous)− 2.90
The corresponding ITR is that if F > 0, assign cycled therapy to this patient, otherwise as-
sign the culture-based therapy. The proposed rule suggests that female gender and increas-
ing age are key determinants for the potential of a patient to benefit from cycled therapy,
which is not surprising since these characteristics are known risk factors for exacerbations.
Counterintuitively, this rule suggests that Pa positivity at baseline leads against the rec-
ommendation for cycled therapy unlike with the prior outcome of increased Pa frequency.
The rule also suggests that patients with genotypes other than delF508 heterozygous and
homozygous may benefit more from cycled therapy as compared to patient with the delF508
mutation. Overall, these results indicate the importance of evaluating multiple endpoints
to evaluate consistency in recommendations for treatment based on these proposed rules.
For RWL-VS-Gaussian, three clinical covariates (age, weight, baseline S. aureus status)
were identified to be unimportant for estimating ITRs. It is well known that the shrinkage
by the ℓ1 penalty causes the estimates of the non-zero coefficients to be biased towards zero
(Hastie et al. 2001). For similar reasons, the estimates from RWL-VS-Gaussian might be
biased. One approach for reducing this bias is to run the ℓ1 penalty method to identify
important covariates, and then fit a model without the ℓ1 term to the selected set of
covariates. We applied RWL-Gaussian to the identified set of covariates. The results are
also presented in Table 5. The obtained annual PE rate was better than that from RWL-
Gaussian alone. Thus variable selection is still helpful to improve the performance.
In summary, the proposed RWL methods can identify potentially useful ITRs. For
example, the estimated ITR for the Pa endpoint in the EPIC trial is that if the baseline
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Pa status is positive, assign culture-based therapy to the patient; if the baseline Pa status
is negative, assign the cycled therapy. As the Pa endpoint was a secondary endpoint in the
trial, the clinical utility of these findings must be weighed in context of all study findings
and safety. But nonetheless identifying such a strategy is important to improve personalized
clinical practice if the strategy is confirmed by future comparative studies.
7 Discussion
In this article, we have proposed a general framework called Residual Weighted Learning
(RWL) to use outcome residuals to estimate optimal ITRs. The residuals may be obtained
from linear models or generalized linear models, and hence RWL can handle various types
of outcomes, including continuous, count and binary outcomes.
The proposed RWL methods appear to achieve better performance compared to other
existing methods as shown in the simulation studies and real data analyses. The goal of
RWL is to improve finite sample performance of OWL methods. It is not surprising that
RWL outperforms OWL in terms of achieving higher value function and smaller variance.
Two-step methods, such as ℓ1-PLS and ℓ1-PoissonReg, are generally parametric. Their
performance largely depends on how close the posited model is to the true model of the
conditional mean outcome. When the model is correctly specified, two-step methods can be
more efficient than nonparametric RWL methods. However, the relationship among clinical
covariates, treatment assignment, and outcome is complex in practice. Misspecified models
may lead to biased estimates.
Both two-step methods and RWL require correct model specification to guarantee their
performance. We consider two levels of model specification. The first one is the model for
the decision boundary; the other is the model for the outcome. Two-step methods, such as
ℓ1-PLS, only specify models for conditional outcomes, and the decision boundary is implied
from these models. Thus the performance of two-step methods are only related to these
models. However, for RWL, the two levels are separated. RWL methods target the decision
boundary directly. The model for decision boundary is more critical to performance. RWL
with Gaussian RBF kernel can approximate any form of decision boundary when the sample
size is sufficiently large. Even when using linear kernels, RWL is more robust to model
misspecification on the decision boundary than the two-step methods. If the conditional
mean outcome is assumed to be linear in the parameters, the decision boundary will be also;
the converse does not hold. For RWL with linear kernel, the decision boundary remains a
simple linear form, while the conditional mean outcome is allowed to be nonlinear.
Another source of robustness of RWL comes from the model for the outcome, in which
we estimate residuals. By Theorem 3.3, no matter how bad the residual estimate is, RWL
is still consistent. In the simulation studies, we have investigated the robustness of residual
estimates on finite samples. We applied the null model, as an example of incorrect model
specification, to estimate residuals, and achieved satisfactory performance. The simulation
studies confirm the robustness of RWL. In this article, we used simple models to obtain the
residuals. However, RWL is quite flexible in the methods used to estimate residuals. When
the sample size is small or the heterogeneous treatment effect is weak, we may consider a
complicated method to accurately estimate residuals to improve the performance of RWL.
Alternatively, nonparametric regression methods, such as support vector regression (Vapnik
1998) or random forests (Breiman 2001), are an option to eliminate model misspecification.
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RWL is closely related to a robust augmented inverse probability weighted estima-
tor (AIPWE) of the value function. AIPWE was first introduced into optimal treatment
regimes by Zhang et al. (2012). Under the setup in this article, i.e., A = {1,−1} and π(a,x)
is known, for any rule d, its associated value function can be estimated by an AIPWE,
AIPWE(d) =
1
n
n∑
i=1
{
I(d(xi) = ai)
π(ai,xi)
Ri − I(d(xi) = ai)− π(ai,xi)
π(ai,xi)
mˆ(xi)
}
,
where mˆ(x) = µˆ1(x)I(d(x) = 1) + µˆ−1(x)I(d(x) = −1), µˆ1(x) is an estimate of E(R|X =
x, A = 1), and µˆ−1(x) is an estimate of E(R|X = x, A = −1). If we take gˆ∗(x) = mˆ(x),
for a fixed d(x), then maximizing AIPWE is equivalent to minimizing the risk in (6).
Hence AIPWE is essentially a “contrast” weighted learning method, where the contrast is
a modelled form that links closely to the residual. Conversely, if we take µˆ1(x) = µˆ−1(x) =
gˆ∗(x), where gˆ∗(x) estimates g∗(x) in (5), then maximizing AIPWE is again equivalent to
minimizing (6). However, RWL can now be obtained by replacing the 0-1 loss with the
smoothed ramp loss, and hence RWL can be viewed as a modification of AIPWE with
alternative useful connections to classification methods.
Variable selection is critical for good performance of RWL, as demonstrated in the sim-
ulation studies and data analyses. We suggest that practical use of RWL should necessarily
be accompanied by variable selection. In Section 4, we introduce the concepts of predic-
tive and prescriptive covariates. It has been noticed in practical settings that the main
effects, rather than treatment-covariate interactions, tend to explain most of the variability
in the outcome, and thus they are important for good prediction (Gunter et al. 2011). It
is not uncommon that interactions between prescriptive covariates and treatment are over-
looked due to their small predictive ability. Hence variable selection techniques designed for
prediction applications might not work perfectly in finding the prescriptive covariates. In
contrast, RWL focuses on treatment-covariate interactions, and variable selection in RWL
only targets the prescriptive covariates.
RWL methods with linear and Gaussian RBF kernels were discussed in this article. The
decision rule from linear RWL is easy to interpret, but at the risk of misspecification. As
a universal kernel, the Gausian RBF kernel is free of model misspecification. An obvious
downside is that the final decision rule may be difficult to interpret, and clinical practitioners
may not be comfortable using “black box” decision rules. One compromise is to apply linear
RWL with a rich set of bases, for example, including two-way and three-way covariate
interactions.
When the endpoint outcome is the survival time, observations are commonly subject to
right censoring because of subject dropout or censoring due to the end of study. Currently,
RWL does not cover this type of outcomes in theory due to the censorship. We recommend
using martingale residuals (Fleming and Harrington 1991) as alternative outcomes. Specif-
ically, residuals in RWL could be opposites of martingale residuals that are estimated by a
Cox proportional hazards model on clinical covariates but excluding treatment assignment.
Actually, the idea is not new. Therneau et al. (1990) suggested that martingale residuals
from a null Cox model could be used as outcomes for Classification and Regression Trees
(CART). The rigourous theoretical justification is under development. Here we provide an
intuitive explanation. Let T denote the survival time, and C denote the censoring time.
The observed data quadruplet is (X, A,R = T ∧ C,∆ = I(T ≤ C)). Firstly, for general
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survival analysis, (R,∆) is seen as the censored outcome. We view the survival data from a
different perspective. We treat ∆ as the outcome, and (X, R) as clinical covariates. In the
framework of counting processes, the martingale residual can be explained as the difference
between the observed number of failures (0 or 1) during the time in the study for a subject
and the expected numbers based on the fitted model. Thus it is almost in line with our
derivation of RWL, although R may not be appropriate as a clinical covariate. Secondly,
martingale residuals from a Cox model fitted excluding a covariate of interest can be used
to determine the appropriate functional form of the covariate (Therneau et al. 1990). If we
estimate martingale residuals by ignoring treatment assignment, they contain information
related to the heterogeneity of treatment effects. Thirdly, martingale residuals have some
properties reminiscent of linear models, for example, the residuals are asymptotically un-
correlated. Moreover, the weighted sum of martingale residuals is zero, which is essential
for RWL to control the treatment matching factor.
Several extensions are worthy of further investigation. In this article, we only consid-
ered two-arm trials. In practice, some trials involve multiple arms, i.e. have three or more
treatment arms. A recent review by Baron et al. (2013) reported that 17.6% of published
randomized clinical trials in 2009 were multiple-arm. Because of the number of possible
comparisons, it is more complex to find ITRs in such trials compared with two-arm trials.
It would thus be worthwhile to extend RWL to multiple-arm trials. In the machine learning
literature, two schools of approaches are generally suggested for multi-category classifica-
tion. One is to directly take all classes into consideration. Multicategory SVMs (Lee et al.
2004) and penalized logistic regression (Zhu and Hastie 2004) are two examples. The other
school is to construct and combine several binary classifiers. One-versus-one, one-versus-all,
and more general error-correcting output codes (Dietterich and Bakiri 1995, ECOC) are
in this school. Similar generalizations may be possible for finding ITRs for multiple-arm
trials.
For chronic diseases, multi-stage dynamic treatment regimes are more useful than single-
stage optimal treatment regimes. In the context of multi-stage decision problems, a dynamic
treatment regime is a sequence of decision rules, one per stage of intervention, for adapting
a treatment plan over time to an individual. Zhao et al. (2014) has extended OWL to
dynamic treatment regimes. Considering the improved performance of RWL over OWL, it
is of interest to extend RWL to dynamic treatment regimes.
The intended use of the estimated optimal ITRs discovered using the proposed approach
is for treating new patients. The theoretical, simulation and data analysis results demon-
strate that such estimated ITRs are likely to lead to improved clinical outcomes for these
patients. However, since the data used for estimating the ITRs should not also be used
for confirmation, it is expected that an additional randomized clinical trial comparing the
estimated ITR with standard of care, or some other suitable treatment comparison, will be
used for confirmation as is typically done for new candidate treatments (Zhao et al. 2011).
APPENDIX A. Proofs
Proof of Lemma 2.1
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Proof. Note that,
E
(
I
(
A 6= d(X))
π(A,X)
∣∣∣X
)
= E
(
I
(
d(X) 6= 1)|X, A = 1)+ E (I(d(X) 6= −1)|X, A = −1) = 1.
(21)
The desired result follows easily.
Proof of Theorem 2.2
Proof. For any measurable function g,
V ar
(
R− g(X)
π(A,X)
I
(
A 6= d(X)))
= V ar
(
R− g˜(X)
π(A,X)
I
(
A 6= d(X)))+ V ar( g˜(X)− g(X)
π(A,X)
I
(
A 6= d(X)))
+2Cov
(
R− g˜(X)
π(A,X)
I
(
A 6= d(X)), g˜(X)− g(X)
π(A,X)
I
(
A 6= d(X))) .
It suffices to show that the covariance term is zero. Applying (21), we have
E
(
R− g˜(X)
π(A,X)
I
(
A 6= d(X))∣∣∣X)
= E
(
R
π(A,X)
I
(
A 6= d(X))∣∣∣X)− g˜(X)E
(
I
(
A 6= d(X))
π(A,X)
∣∣∣X
)
= 0.
Note that
g˜(X) = E
(
R
π(A,X)
I
(
A 6= d(X))∣∣∣X)
= E(R|X, A = 1)I(d(X) 6= 1) + E(R|X, A = −1)I(d(X) 6= −1). (22)
Thus we have,
E
(
R− g˜(X)
π(A,X)2
I
(
A 6= d(X))∣∣∣X)
= E (R− g˜(X)|X, A = 1) I(d(X) 6= 1)/π(1,X)
+E (R− g˜(X)|X, A = −1) I(d(X) 6= −1)/π(−1,X)
= 0.
The desired result follows easily.
Proof of Theorem 3.1
Proof. Given X = x, for any measurable function f , similar reasoning to that used in the
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proof of Lemma 2.1 yields,
E
(
T
(
Af(X)
)
π(A,X)
∣∣∣X = x
)
= 2.
Then the conditional T -risk is
E
(
R− g(X)
π(A,X)
T (Af(X))
∣∣X = x)
= E(R|X = x, A = 1)T (f(x)) + E(R|X = x, A = −1)T (−f(x))− 2g(x)
= (E(R|X = x, A = 1)− E(R|X = x, A = −1))T (f(x))
+2E(R|X = x, A = −1)− 2g(x). (23)
If E [R|X = x, A = 1] − E [R|X = x, A = −1] > 0, any function f(x) ≥ 1 minimizes the
conditional T -risk; similarly, if E [R|X = x, A = 1]−E [R|X = x, A = −1] < 0, any function
f(x) ≤ −1 minimizes the conditional T -risk. For either case, sign(f∗T,g) = d∗.
For the second part, by applying (23),
E
(
R− g(X)
π(A,X)
T (Ad∗(X))|X = x
)
− E
(
R− g(X)
π(A,X)
T (Af∗T,g(X))|X = x
)
= (E(R|X = x, A = 1)− E(R|X = x, A = −1)) (T (d∗(x))− T (f∗T,g(x))) = 0.
The desired result follows by taking expectations on both sides.
Proof of Theorem 3.2
Proof. Given X = x. By applying (23), for any measurable function f , we have
E
(
R− g(X)
π(A,X)
T (Af(X))|X = x
)
− E
(
R− g(X)
π(A,X)
T (Af∗T,g(X))|X = x
)
= (E(R|X = x, A = 1)− E(R|X = x, A = −1)) (T (f(x))− T (f∗T,g(x))) .
Similarly,
E
(
R
π(A,X)
I(A 6= sign(f(X)))|X = x
)
− E
(
R
π(A,X)
I(A 6= d∗(X))|X = x
)
= (E(R|X = x, A = 1)− E(R|X = x, A = −1)) (I(sign(f(x)) 6= 1)− I(d∗(x) 6= 1)) .
From the proof of Theorem 3.1, when E(R|X = x, A = 1) > E(R|X = x, A = −1),
f∗T,g(x) ≥ 1 and d∗(x) = 1, so T (f∗T,g(x)) = 0 and I(d∗(x) 6= 1) = 0; when E(R|X = x, A =
1) < E(R|X = x, A = −1), f∗T,g(x) ≤ −1 and d∗(x) = −1, so T (f∗T,g(x)) = 2 and I(d∗(x) 6=
1) = 1. Note that, for any measurable function f , 1 ≥ T (f(x)) − I(sign(f(x)) 6= 1) ≥ 0.
Thus it is easy to check that when E(R|X = x, A = 1) > E(R|X = x, A = −1),
T (f(x))− T (f∗T,g(x)) ≥ I(sign(f(x)) 6= 1)− I(d∗(x) 6= 1),
and when E(R|X = x, A = 1) < E(R|X = x, A = −1),
T (f(x))− T (f∗T,g(x)) ≤ I(sign(f(x)) 6= 1)− I(d∗(x) 6= 1).
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So, for either case, we have
E
(
R
π(A,X)
I(A 6= sign(f(X)))|X = x
)
− E
(
R
π(A,X)
I(A 6= d∗(X))|X = x
)
≤ E
(
R− g(X)
π(A,X)
T (Af(X))|X = x
)
− E
(
R− g(X)
π(A,X)
T (Af∗T,g(X))|X = x
)
.
The desired result follows by taking expectations on both sides.
Proof of Theorem 3.3
Proof. Let L(h, b) = (R−g(X))T (A(h(X)+b))/π(A,X). For simplicity, we denote fDn,λn ,
hDn,λn and bDn,λn by fn, hn and bn, respectively. By the definition of hDn,λn and bDn,λn ,
we have, for any h ∈ HK and b ∈ R,
Pn(L(hn, bn)) ≤ Pn(L(hn, bn)) + λn
2
||hn||2K ≤ Pn(L(h, b)) +
λn
2
||h||2K ,
where Pn denotes the empirical measure of the observed data. Then, lim supn Pn(L(hn, bn)) ≤
P(L(h, b)) = RT,g(h+ b) with probability 1. This implies
lim sup
n
Pn(L(hn, bn)) ≤ inf
h∈HK ,b∈R
RT,g(h+ b) ≤ P(L(hn, bn))
with probability 1. It suffices to show Pn(L(hn, bn))− P(L(hn, bn))→ 0 in probability.
We first obtain a bound for ||hn||K . Since Pn(L(hn, bn)) + λn||hn||2K/2 ≤ Pn(L(h, b)) +
λn||h||2K/2, for any h ∈ HK and b ∈ R, we can choose h = 0 and b = 0 to obtain,
Pn(L(hn, bn))+λn||hn||2K/2 ≤ Pn((R− g(X))/π(A,X)). Note that 0 ≤ T (u) ≤ 2. We thus
have,
λn||hn||2K ≤ 2Pn(|R − g(X)|/π(A,X)) ≤ 2M0.
Let M1 =
√
2M0. Then the HK norm of
√
λnhn is bounded by M1.
Next we obtain a bound for bn. We claim that there is a global solution (hn, bn) such
that hn(xi) + bn ∈ [−1, 1] for some i. Suppose there is a global solution (h′n, b′n) such that
|h′n(xi) + b′n| > 1 for all i. Let δ = |h′n(xi0) + b′n| = min1≤i≤n |h′n(xi) + b′n| > 1. Then let
hn = h
′
n and bn = b
′
n − (δ − 1)sign(h′n(xi0) + b′n). It is easy to check that hn(xi0) + bn = 1
if h′n(xi0) + b′n > 1, and hn(xi0) + bn = −1 if h′n(xi0) + b′n < −1; furthermore when i 6= i0,
hn(xi) + bn ≥ 1 if h′n(xi) + b′n > 1, and hn(xi) + bn ≤ −1 if h′n(xi) + b′n < −1. So
T (hn(xi) + bn) = T (h
′
n(xi) + b
′
n) for all i. Hence (hn, bn) is a global solution and satisfies
our claim. Now if a solution (hn, bn) satisfies our claim, we then have,
|bn| ≤ 1 + |hn(xi0)| ≤ 1 + ||hn||∞.
Note that ||h||∞ ≤ CK ||h||K . We have,
|
√
λnbn| ≤
√
λn + CK
√
λn||hn||K .
Since λn → 0, and CK and
√
λn||hn||K are both bounded, we have |
√
λnbn| is bounded too.
Let the bound be M2, i.e. |
√
λnbn| ≤M2.
Note that the class {√λnh : ||
√
λnh||K ≤ M1} is a Donsker class. So {
√
λn(h + b) :
38
||√λnh||K ≤M1, |
√
λnb| ≤M2} is also P-Donsker. Consider the function
Tλ(u) =


2
√
λ if u < −√λ,
2
√
λ− 1√
λ
(
√
λ+ u)2 if −
√
λ ≤ u < 0,
1√
λ
(
√
λ− u)2 if 0 ≤ u <
√
λ,
0 if u ≥ √λ.
We have Tλ(
√
λu) =
√
λT (u). Since Tλ(u) is a Lipschitz continuous function with Lips-
chitz constant equal to 2, and R−g(X)π(A,X) is bounded, the class {
√
λnL(h, b) : ||
√
λnh||K ≤
M1, |
√
λnb| ≤M2} is also P-Donsker. Therefore,√
nλn(Pn − P)L(hn, bn) = Op(1).
Consequently, from nλn →∞, Pn(L(hn, bn))− P(L(hn, bn))→ 0 in probability.
Proof of Lemma 3.4
Proof. Fix any 0 < ǫ < 1. d∗(x) = sign(E(R|X = x, A = 1) − E(R|X = x, A = −1))
is measurable. Since µ is regular, using Lusin’s theorem in measure theory, we know that
d∗(x) can be approximated by a continuous function f ′(x) ∈ C(X ) such that µ(f ′(x) 6=
d∗(x)) ≤ ǫ4M . Thus
E
(
R− g(X)
π(A,X)
T (Af ′(X))|X = x
)
− E
(
R− g(X)
π(A,X)
T (Ad∗(X))|X = x
)
= (E(R|X = x, A = 1)− E(R|X = x, A = −1)) (T (f ′(x))− T (d∗(x))) .
Then,
RT,g(f ′)−R∗T,g = |RT,g(f ′)−RT,g(d∗)|
=
∣∣∣ ∫ (E(R|X = x, A = 1)− E(R|X = x, A = −1)) (T (f ′(x))− T (d∗(x)))µ(dx)∣∣∣
≤
∫ ∣∣∣ (E(R|X = x, A = 1)− E(R|X = x, A = −1)) ∣∣∣∣∣∣T (f ′(x))− T (d∗(x))∣∣∣
I(f ′(x) 6= d∗(x))µ(dx).
Since |R| ≤M and 0 ≤ T (u) ≤ 2,
RT,g(f ′)−R∗T,g < ǫ
Since K is universal, there exist a function f ′′ ∈ HK such that ||f ′′ − f ′||∞ < ǫ4M . Note
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that T (·) is Lipschitz continuous with Lipschitz constant 2. Similarly,
|RT,g(f ′′)−RT,g(f ′)|
=
∣∣∣ ∫ (E(R|X = x, A = 1)− E(R|X = x, A = −1)) (T (f ′′(x))− T (f ′(x)))µ(dx)∣∣∣
≤ 2
∫ ∣∣∣ (E(R|X = x, A = 1)− E(R|X = x, A = −1)) ∣∣∣∣∣∣f ′(x)− f ′(x)∣∣∣µ(dx) < ǫ.
By combining the two inequalities, we have
RT,g(f ′′)−R∗T,g < 2ǫ.
Noting that f ′′ ∈ HK and letting ǫ→ 0, we obtain the desired result.
Proof of Theorem 3.6
Proof. The proof follows the idea in Devroye et al. (1996, Theorem 7.2). Since the proof is
very similar, we only provide a sketch to save space.
Let b = 0.b1b2b3 · · · be a real number on [0, 1] with the given binary expansion, and let B
be a random variable uniformly distributed on [0, 1] with expansion B = 0.B1B2B3 · · · . Let
us restrict ourselves to a random variable X with the support {x1,x2, · · · } where xi ∈ X .
For simplicity, we recode the support of X as {1, 2, · · · }. Let
P (X = i) = pi, i ≥ 1, (24)
where p1 ≥ p2 ≥ · · · > 0, and
∑∞
i=n+1 pi ≥ max(8cn, 32npn+1) for every n. Such pi’s
exist by Devroye et al. (1996, Lemma 7.1). Let A ∈ {1,−1} be a binomial variable with
π(A,X) = 0.5. For a given b, set R = AM if bX = 1, and R = −AM if bX = 0. Then the
Bayes rule is d∗(X) = (2 ∗ bX − 1). Thus each b ∈ [0, 1] describes a different distribution of
(X, A,R). Introduce the shortened notation Dn = {(X1, A1, R1), · · · , (Xn, An, Rn)}. Let
dn be a rule generated by data Dn. Define d
i
n = dn(i) for i = 1, · · · , n. Let ∆Rn(b) be the
excess risk of the rule dn for the distribution parametrized by b, and ∆Rn(B) be the excess
risk of the rule dn for the random distribution.
∆Rn(B)
= E
[
R
π(A,X)
I(A 6= dn(X))
∣∣∣B]− E [ R
π(A,X)
I(A 6= d∗(X))
∣∣∣B]
= E
[(
E(R|B,X, A = 1)− E(R|B,X, A = −1))(I(dn(X) 6= 1)− I(d∗(X) 6= 1))∣∣B]
= 2ME
(
I(dn(X) 6= d∗(X))
∣∣B)
= 2ME
(
I(dn(X) 6= 2BX − 1)
)
.
Let Ln(B) = E
(
I(dn(X) 6= 2BX − 1)
)
. Then we have,
Ln(B) =
∞∑
i=1
piI(d
i
n 6= 2Bi − 1).
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Following the same arguments used in Devroye et al. (1996, Theorem 7.2), we have
P (Ln(B) < 2cn|Dn) ≤ P (
∞∑
i=n+1
piBi < 2cn) ≤ e−2n.
Hence we have
sup
b
inf
n
E
(
Ln(b)
2cn
)
≥ E
(
E
(
inf
n
(
Ln(b)
2cn
∣∣∣X1,X2, · · ·)))
≥ E
(
1−
∞∑
i=1
E(P (Ln(B) < 2cn|Dn)|X1,X2, · · · )
)
≥ 1−
∞∑
i=1
e−2n =
e2 − 2
e2 − 1 >
1
2
.
Here we are omitting many steps. Refer to Devroye et al. (1996, Theorem 7.2) for details.
The conclusion is that there exists a b for which ∆Rn(b) ≥ 2Mcn, n = 1, 2, · · · .
Proof of Theorem 3.7
Proof. Define the random variable S = R−g(X)π(A,X) . We consider a probability measure on the
triplet (X, A, S) instead of on (X, A,R). Let Dn = {Xi, Ai, Si}ni=1 be independent random
variables with the same distribution as (X, A, S). Let Pn be the empirical measure on Dn.
For simplicity, we denote fDn,λn , hDn,λn and bDn,λn by fn, hn and bn, respectively. Let
(h˜λn , b˜λn) be a solution of the following optimization problem:
min
h∈HK ,b∈R
λn
2
||h||2K +RT,g(h+ b).
Let L(h, b) = ST (A(h(X) + b)). Then
RT,g(fn)−RT,g(f∗T,g)
≤ (P− Pn)L(hn, bn) + (λn
2
||hn||2 + PnL(hn, bn))− (λn
2
||h˜λn ||2 + PnL(h˜λn , b˜λn))
+(Pn − P)L(h˜λn , b˜λn) +A(λn)
≤ (P− Pn)L(hn, bn) + (Pn − P)L(h˜λn , b˜λn)) +A(λn).
We first estimate the second term by the Hoeffding inequality (Steinwart and Christmann
2008, Theorem 6.10). Since |L(h, b)| ≤ 2M0, we thus have, with probability at least 1−δ/2,
(Pn − P)L(h˜λn , b˜λn) ≤M0
√
2 log 2δ
n
. (25)
By the arguments used in the proof of Theorem 3.3, we have ||hn||K ≤
√
2M0
λn
and
|bn| ≤ 1+CK
√
2M0
λn
. Then let F = {(h, b) ∈ HK ×R : ||h||K ≤
√
2M0
λn
, |b| ≤ 1+CK
√
2M0
λn
}.
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Let L˜(h, b) = S
[
T (A(h(X) + b))− 1
]
. For the first term, (P− Pn)L(hn, bn),
(P− Pn)L(hn, bn) ≤ sup
(h,b)∈F
(P− Pn)L(h, b)
= sup
(h,b)∈F
(P− Pn)L˜(h, b) + (P− Pn)L(0, 0).
When an (xi, ai, si) triplet changes, the random variable sup(h,b)∈F (P − Pn)L˜(h, b) can
change by no more than 2M0n . McDiarmid’s inequality (Bartlett and Mendelson 2002,
Theorem 9) then implies that with probability at least 1− δ/4,
sup
(h,b)∈F
(P− Pn)L˜(h, b) ≤ E sup
(h,b)∈F
(P − Pn)L˜(h, b) +M0
√
2 log(4/δ)
n
.
A similar argument, together with the fact that EPnL(0, 0) = PL(0, 0), shows that with
probability at least 1− δ/2,
(P − Pn)L(hn, bn) ≤ E sup
(h,b)∈F
(P− Pn)L˜(h, b) + 2M0
√
2 log(4/δ)
n
.
LetD′n = {X ′i, A′i, S′i}ni=1 be an independent sample with the same distribution as (X, A, S).
Let P′n denote the empirical measure on D′n. Let σ be a uniform {±1}-valued random
variable, and σ1, . . . , σn be n independent copies of σ. Then we have
E sup
(h,b)∈F
(P− Pn)L˜(h, b) = E sup
(h,b)∈F
E
(
P
′
nL˜(h, b)− PnL˜(h, b)
∣∣∣Dn)
≤ 2E sup
(h,b)∈F
PnσL˜(h, b)
≤ 2EE
(
sup
(h,b)∈F
|PnσL˜(h, b)|
∣∣∣Si, Ai, i = 1, . . . , n)
≤ 16M0
n
E sup
(h,b)∈F
∣∣∣ n∑
i=1
σi
(
h(Xi) + b
)∣∣∣.
The last inequality is due to the contraction inequality (Ledoux and Talagrand 1991, Corol-
lary 3.17). The preceding can be further majorized by using Lemma 22 in Bartlett and
Mendelson (2002),
E sup
(h,b)∈F
(P − Pn)L˜(h, b) ≤ 16M0
n
E sup
(h,b)∈F
∣∣∣ n∑
i=1
σih(Xi)
∣∣∣+ 16M0
n
(1 + CK
√
2M0
λn
)E
∣∣∣ n∑
i=1
σi
∣∣∣
≤ 16M0√
n
√
2M0
λn
CK +
16M0√
n
(1 + CK
√
2M0
λn
)
=
16M0√
n
(1 + 2CK
√
2M0
λn
).
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Then we have that with probability at least 1− δ/2,
(P− Pn)L(hn, bn) ≤ 16M0√
n
(1 + 2CK
√
2M0
λn
) + 2M0
√
2 log(4/δ)
n
. (26)
By the assumption, (25), and (26), we obtain that with probability at least 1− δ,
RT,g(fn)−R∗T,g ≤M0
√
2 log(2/δ)
n
+
16M0√
n
(1 + 2CK
√
2M0
λn
) + 2M0
√
2 log(4/δ)
n
+ cλβn.
Let λn = n
− 1
2β+1 . By Theorem 3.2, we obtain the final result that with probability at least
1− δ,
R(sign(fn))−R∗ ≤ c˜
√
log(4/δ)n−
β
2β+1 .
Here c˜ =M0
(
16 + 3
√
2 + 32CK
√
2M0
)
+ c. This completes the proof.
Proof of Lemma 3.9
Proof. We first introduce a lemma. It is revised from Lemma 4.1 in Steinwart and Scovel
(2007) to adapt to our settings for individualized treatment rules.
Lemma A.1. Let X be the closed unit ball of the Euclidean space Rp, and P be a distri-
bution on X × A ×M with regular marginal distribution on X. Recall δ(x) = E(R|X =
x, A = 1)− E(R|X = x, A = −1) for x ∈ X . On X´ := 3X we define
δ´(x) =


δ(x) if ||x|| ≤ 1,
δ
(
x
||x||
)
otherwise,
where || · || is the Euclidean norm. We also write X´+ = {x ∈ X´ : δ´(x) > 0}, and
X´− = {x ∈ X´ : δ´(x) < 0}. Finally let B(x, r) denote the open ball of radius r about x in
R
p. Then for x ∈ X+, we have B(x, τx) ⊂ X´+, and for x ∈ X−, we have B(x, τx) ⊂ X´−.
The proof is simple, and is the same as that of Lemma 4.1 in Steinwart and Scovel
(2007). We omit the proof here. In the lemma, the support is enlarged to ensure that all
balls of the form B(x, τx) are contained in the enlarged support. We return to the proof of
Lemma 3.9.
Let L2(R
p) be the L2-space on R
p with respect to Lebesque measure, and Hσ(Rp) be
the RKHS of the Gaussian RBF kernel Kσ. The linear operator Vσ : L2(R
p) → Hσ(Rp)
defined by
Vσℓ(x) =
(2σ)d/2
πd/4
∫
Rp
e−2σ
2||x−y||2ℓ(y)dy, ℓ ∈ L2(Rp), x ∈ Rp,
is an isometric isomorphism (Steinwart et al. 2006). Thus we have,
A(λ) ≤ inf
ℓ∈L2(Rp)
λ
2
||ℓ||2L2(Rp) +RT,g(Vσℓ)−R∗T,g. (27)
43
With the notation of Lemma A.1 we fix a measurable f´P : X´ → [−1, 1] that satisfies f´P = 1
on X´+, f´P = −1 on X´−, and f´P = 0 otherwise. For ℓ := (σ2/π)p/4f´P , we immediately
obtain,
||ℓ||L2(Rp) ≤
(
81σ2
π
)p/4
θ(p), (28)
where θ(p) denotes the volume of X . As shown in the proof of Theorem 3.2, we have
RT,g(Vσℓ)−R∗T,g = E(|δ(x)| · |T (Vσℓ(x))− T (d∗(x))|) ≤ 2E(|δ(x)| · |Vσℓ(x)− d∗(x)|).
Following the same derivations as in the proof of Theorem 2.7 of Steinwart and Scovel
(2007), we also obtain
|Vσℓ(x)− d∗(x)| ≤ 8e−σ2τ2x/(2p).
The geometric noise assumption yields
RT,g(Vσℓ)−R∗T,g ≤ 16E(|δ(x)|e−σ
2τ2
x
/(2p)) ≤ 16C(2p)qp/2σ−qp. (29)
Combining (27), (28) and (29) yields
A(λ) ≤
(
81σ2
π
)p/2
θ2(p)λ/2 + 16C(2p)qp/2σ−qp.
The desired result now follows by taking σ = λ
− 1
(q+1)p .
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